Asia Pacific Type 1 Sbs If Short Bowel Syndrome With Intestinal Failure Treatment Market
Tamaño del mercado en miles de millones de dólares
Tasa de crecimiento anual compuesta (CAGR) :
% 
USD
210.71 Million
USD
369.92 Million
2025
2033
 Período de pronóstico |
2026 –2033 |
 Tamaño del mercado (año base) |
USD 210.71 Million |
 Tamaño del mercado (año de pronóstico) |
USD 369.92 Million |
 Tasa de crecimiento anual compuesta (CAGR) |
% |
| Jugadoras de los principales mercados |
|
Centro de Tratamiento de la Farmacéutica y el Tratamiento de la Farmacéutica (Inteligencia de Fin de la Salud) Tendencias y pronósticos industriales a 2033
Asia-Pacífico Tipo 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) TratamientoPanorama general del mercado
El mercado de tratamiento de tipo Asia-Pacífico 1 SBS-IF (síndrome de intestino corto con insuficiencia intestinal) fue valorado enUSD 210.71 Millones en 2025y se prevé que alcanceUSD 369.92 Millones en 2033, creciendo en unCAGR of 8.0% from 2026 to 2033. El mercado está presenciando un crecimiento constante impulsado por la creciente prevalencia de insuficiencia intestinal asociada a las principales reseecciones intestinales, la enfermedad de Crohn, isquemia mesentérica, traumatismo, trastornos gastrointestinales congénitos y complicaciones postoperatorias que requieren una gestión nutritiva y farmacológica intensiva.
La creciente dependencia de la nutrición parenteral, los avances en las terapias analógicas GLP-2, el aumento de la conciencia respecto de los programas de rehabilitación intestinal y la creciente disponibilidad de servicios de nutrición parenteral (HPN) en el hogar están apoyando significativamente la expansión del mercado. Además, las mejoras en la atención gastrointestinal multidisciplinar, la gestión de SBS pediátrica y las intervenciones nutricionales personalizadas están acelerando la adopción del tratamiento a nivel mundial.
Principales tendencias del mercado "
- Japón es el país dominante en el mercado de tratamiento Tipo 1 SBS-IF de Asia-Pacífico, lo que representa la mayor cuota de mercado de 23,14% en 2025. Esta predominio está impulsada por la infraestructura sanitaria avanzada del país, altas tasas de diagnóstico y tratamiento para trastornos gastrointestinales raros, y una fuerte adopción de nutrición parental innovadora y terapias biológicas.
- Japón es también el país de más rápido crecimiento en el mercado, proyectado para expandirse en un CAGR de 9,0% durante el período de previsión de 2026-2033. Este crecimiento se ve alimentado por el aumento de la conciencia y el diagnóstico temprano del síndrome de Short Bowel – falla intestinal (SBS-IF), el aumento de la demanda de terapias nutricionales avanzadas, y las inversiones en gestión de enfermedades raras y el desarrollo innovador del tratamiento.
- Mediante la modalidad de tratamiento, la terapia de apoyo nutricional dominó el mercado de tratamiento tipo Asia-Pacífico 1 SBS-IF, con la mayor cuota de mercado de 42,51% en 2025, impulsado por el papel crítico de la nutrición parenteral, alimentación de entrada, gestión de electrolitos y rehabilitación nutricional a largo plazo en la supervivencia y recuperación de pacientes SBS-IF.
- Por modalidad de tratamiento, las terapias avanzadas emergentes son el segmento de crecimiento más rápido del mercado, proyectado para expandirse en una CAGR de 8,3% (2026–2033), apoyada por la adopción creciente de análogos GLP-2, terapias de factor de crecimiento intestinal, enfoques de medicina regenerativa, terapéuticas basadas en microbioma y nuevas tecnologías de rehabilitación intestinal.
- Por atribución de mercado, el mercado central SBS-IF dominaba el mercado, con una cuota de mercado de 56.88% en 2025, impulsada por intervenciones terapéuticas directas dirigidas específicamente a la gestión de fallas intestinales y dependencia nutricional a largo plazo.
- Por atribución al mercado, el mercado atribuible SBS-IF es el segmento de mayor crecimiento, proyectado para expandirse en un CAGR de 8,3% (2026–2033), apoyado por el aumento de las tasas de diagnóstico, la cobertura de reembolso más amplia y la ampliación de los servicios de atención de apoyo asociados con complicaciones relacionadas con SBS.
- Por fase de gestión de enfermedades, el segmento de fase aguda (tipo 1 SBS-IF) dominaba el mercado, con una cuota de mercado de 48,43% en 2025, debido a altas tasas de hospitalización, requisitos intensivos de apoyo nutricional y gestión postoperatoria de atención crítica.
- Por fase de gestión de enfermedades, la fase de adaptación es el segmento de mayor crecimiento del mercado, proyectado para expandirse en un CAGR de 8,2% (2026–2033), impulsado por el creciente enfoque en la rehabilitación intestinal, la reducción gradual de la dependencia parenteral y las estrategias de optimización de la recuperación a largo plazo.
Tamaño del mercado
- Valor mundial del mercado (2025): 210,71 millones de dólares
- Valor de mercado esperado (2033): USD 369,92 millones
- CAGR prefabricado (2026–2033): 8.0%
- País líder en 2025: Japón
- País de cultivo más rápido: China
Report Scope and Asia-Pacific Type 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) TreatmentMarket Segmentation
|
Atributos |
Tipo 1 SBS-IF (Síndrome del intestino corto con falla intestinal)Market Insights |
|
Segmentos cubiertos |
|
|
Países cubiertos |
Asia y el Pacífico · Japón China · Corea del Sur · India · Singapur · Tailandia · Indonesia Malasia · Filipinas · Australia · Nueva Zelandia · Hong Kong · Taiwán · El resto de Asia-Pacífico |
|
Principales jugadores del mercado |
· Stanford Health Care (U.S.) · Hospira (Estados Unidos, ahora parte de Pfizer) · Cuidado de Salud Aurora (EE.UU.) · Takeda Pharmaceutical Company Limited (Japón) · Fresenius Kabi AG (Alemania) · Grifols (España) · Laboratorios Abbott (U.S.) · Shandong Qidu Pharmaceutical Co., Ltd. (China) · Ferring Pharmaceuticals (Suiza) · UF Health (University of Florida Health) (U.S.) · Baxter International (U.S.) · VectivBio AG (Suiza) · Farmacéuticos de Ironwood (Estados Unidos) · Hikma Pharmaceuticals PLC (Jordania) · Nutricia (Países Bajos) · Amsino International, Inc. (U.S.) · B. Braun Melsungen AG (Alemania) · ContinuumRx (U.S.) · Jedux Parenteral Private Limited (India) · Beverly Hills Digestive Care (U.S.) · Elección de la Nutrición Parenteral LLC (U.S.) · Sistemas Integrados de Atención (U.S.) · Camvitaa (No verificado públicamente) · Regenesis de Eclipse (No verificada públicamente) · Laboratoire Dielen (Francia) · Vision Parenteral Pvt. Ltd. (India) · Atención de la salud aguda (India) · Nutrego (No verificado públicamente) · Pharmko, Inc. (U.S.) · Soluciones de infusión (U.S.) · NUTRICIA North America (U.S.) · Terapia Napo (Italia) · Moog Inc. (Estados Unidos) · ICU Medical, Inc. (U.S.) · Puerto Life Sciences Pvt. Ltd (India) · Bausch Health Companies (Canadá) |
|
Oportunidades de mercado |
· Ampliación de la nutrición parenteral doméstica (HPN) y programas de rehabilitación intestinal ambulatoria · Aumento de la adopción de análogos GLP-2 y terapias biológicas avanzadas · Aumento del desarrollo de nutrición personalizada y terapias intestinales regenerativas |
|
Valor añadido Data Infosets |
Además de las ideas sobre escenarios de mercado como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado comisariados por Data Bridge Market Research también incluyen análisis profundos de expertos, epidemiología de pacientes, análisis de tuberías, análisis de precios y marco regulatorio. |
Asia-Pacífico Tipo 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Tratamiento Mercado Tendencias
Tendencia: creciente adopción de terapias de rehabilitación intestinal y de análisis GLP-2
El mercado de tratamiento tipo 1 SBS-IF está cambiando cada vez más hacia estrategias integrales de rehabilitación intestinal que combinan optimización nutricional, terapia farmacológica y intervenciones mínimamente invasivas. Las terapias avanzadas como los análogos GLP-2 están ganando una tracción significativa debido a su capacidad para mejorar la absorción intestinal, reducir la dependencia de la nutrición parenteral, y mejorar la calidad de vida del paciente. Los proveedores de atención médica también se centran cada vez más en modelos multidisciplinarios de atención que integran a gastroenterólogos, dietistas, cirujanos y especialistas en atención a domicilio.
Asia-Pacífico Tipo 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Tratamiento Dinámica del mercado
Conductor del mercado clave: Prevalencia creciente de la falla intestinal y dependencia en la nutrición de la parenteral
La creciente incidencia de reseecciones gastrointestinales, enfermedad de Crohn, enfermedad intestinal isquémica, anomalías intestinales congénitas y complicaciones postoperatorias aumenta significativamente la prevalencia de SBS-IF a nivel mundial. Los pacientes con insuficiencia intestinal grave requieren apoyo nutricional a largo plazo, manejo de fluidos y terapias especializadas, lo que impulsa una fuerte demanda de soluciones avanzadas de tratamiento SBS-IF y programas de nutrición parenteral.
Restricción clave / desafío: elevados costos de tratamiento y cuidado a largo plazo
Uno de los principales retos del mercado es el alto costo asociado con la nutrición parenteral a largo plazo, terapias biológicas, formulaciones nutricionales especializadas y la gestión multidisciplinaria de la atención. Además, los pacientes sometidos a tratamiento prolongado se enfrentan a riesgos de infecciones relacionadas con el catéter, complicaciones hepáticas, desequilibrios metabólicos y menor accesibilidad a centros especializados de rehabilitación intestinal, especialmente en las regiones en desarrollo.
Oportunidad del mercado clave: Ampliación de la atención a domicilio y terapias biológicas avanzadas
La creciente adopción de servicios de salud en el hogar y tecnologías de infusión portátiles está creando oportunidades significativas en el mercado de tratamiento Tipo 1 SBS-IF. Aumentar la disponibilidad de programas de nutrición parenteral en el hogar está mejorando la comodidad del paciente y reduciendo los costos de hospitalización. Además, se espera que la investigación en curso en análogos GLP-2, medicina regenerativa, terapéutica microbioma e ingeniería de tejido acelere la innovación y mejore los resultados de los pacientes a largo plazo en todo el panorama global del tratamiento SBS-IF.
Asia-Pacífico Tipo 1 SBS-IF (Short Bowel Síndrome con falla intestinal)
El mercado de tratamiento tipo Asia-Pacífico 1 SBS-IF (síndrome de intestino corto con insuficiencia intestinal) se segmenta sobre la base de la modalidad de tratamiento, atribución de mercado, fase de gestión de enfermedades, tipo de paciente, ruta de administración, usuario final y canal de distribución.
- Por Modalidad de Tratamiento
Sobre la base de la modalidad de tratamiento, el mercado de tratamiento tipo SBS-IF de Asia-Pacífico se segmenta en terapia de apoyo nutricional, terapia farmacológica, tratamiento quirúrgico e intervencionista y terapias avanzadas emergentes. El segmento de la terapia de apoyo nutricional dominó el mercado con una cuota de 42,51% en 2025, impulsada por una alta dependencia de los programas de nutrición parenteral (PN) y nutrición parenteral (HPN) para gestionar la malabsorción severa y el desequilibrio a largo plazo en pacientes con SBS-IF.
Se espera que el segmento de terapias avanzadas emergentes sea testigo del crecimiento más rápido en un CAGR de 8,3% de 2026 a 2033, apoyado por la creciente adopción de análogos GLP-2, protocolos de rehabilitación intestinal y enfoques de medicina regenerativa dirigidos a reducir la dependencia de PN a largo plazo y mejorar los resultados de adaptación intestinal en todo Japón, China y Australia.
- By Market Attribution
Sobre la base de la atribución del mercado, el mercado de tratamiento SBS-IF de tipo Asia Pacífico se segmenta en el mercado básico SBS-IF, el mercado atribuible SBS-IF y el mercado adyacente/no específico. El segmento central del mercado SBS-IF dominaba en 2025 con una participación del 56,88%, impulsado por el manejo clínico directo de pacientes con insuficiencia intestinal confirmada que requieren apoyo nutricional y terapéutico continuo.
Se espera que el segmento de mercado atribuible SBS-IF sea testigo de una expansión moderada en una CAGR de 8,3% de 2026 a 2033, con el apoyo de una mejor precisión diagnóstica, la identificación creciente de casos de insuficiencia intestinal secundaria y la expansión de redes especializadas de atención gastroenterológica en las economías emergentes de Asia y el Pacífico.
- Por fase de gestión de enfermedades
Sobre la base de la fase de gestión de enfermedades, el mercado se segmenta en fase aguda (Tipo 1 SBS-IF), fase de adaptación y fase de recuperación. El segmento de fase aguda dominó el mercado en 2025 con una cuota de 48,43%, impulsada por requisitos críticos de atención incluyendo estabilización inmediata, iniciación de nutrición parenteral y monitoreo intensivo en pacientes recién diagnosticados.
Se espera que el segmento de adaptación sea testigo del crecimiento más rápido en una CAGR de 8,2% de 2026 a 2033, impulsado por el aumento del uso de terapias de adaptación intestinal, intervenciones farmacológicas y estrategias de optimización nutricional a largo plazo para reducir la dependencia de la PN.
- Por tipo de paciente
Sobre la base del tipo de paciente, el mercado de tratamiento tipo SBS-IF de Asia-Pacífico se segmenta en pacientes adultos y pediátricos. El segmento adulto dominó el mercado en 2025 con una cuota del 71,50%, principalmente debido a la mayor incidencia después de reseecciones quirúrgicas causadas por la enfermedad de Crohn, isquemia, trauma y complicaciones postoperatorias.
Se espera que el segmento pediátrico experimente un mayor crecimiento en una CAGR de 8,2% de 2026 a 2033, impulsado por el aumento de los trastornos intestinales congénitos como la enterocolitis necrotizante y la atresia intestinal, junto con mejores tasas de supervivencia en las unidades de cuidados intensivos neonatales.
- Por Ruta de Administración
Sobre la base de la vía de administración, el mercado se segmenta en rutas intravenosas, subcutáneas, orales y de entrada. El segmento intravenoso dominaba el mercado en 2025 con una cuota de 49,23%, impulsada por el uso amplio de la nutrición parenteral, la terapia con fluidos intravenosos y la administración intravenosa de drogas en casos SBS-IF graves.
Se espera que el segmento subcutáneo sea testigo del crecimiento más rápido en una CAGR de 8,3% de 2026 a 2033, con el apoyo de la adopción creciente de biológicas inyectables como terapias analógicas GLP-2 que mejoran la absorción intestinal y reducen la dependencia de la nutrición intravenosa.
- Por Usuario final
Sobre la base del usuario final, el mercado se segmenta en hospitales (atención acústica), atención a domicilio (programas de HPN), configuración de ICU, centros especiales de GI y hospitales de especialidades pediátricas. El segmento de hospitales (cuidado agudo) dominaba el mercado en 2025 con una cuota de 38,78%, impulsada por altas tasas de hospitalización para la gestión aguda, complicaciones quirúrgicas e iniciación de la terapia de nutrición parenteral a largo plazo.
Se espera que el segmento de atención en el hogar (programas de HPN) sea testigo del crecimiento más rápido en una CAGR del 8,6% de 2026 a 2033, con el apoyo de la adopción creciente de modelos de atención en el hogar, estrategias de contención de costos y tecnologías de infusión mejoradas que permitan la gestión ambulatoria a largo plazo.
- Por canal de distribución
Sobre la base del canal de distribución, el mercado de tratamiento Asia-Pacífico Tipo 1 SBS-IF se segmenta en farmacia hospitalaria, farmacia especializada, farmacia minorista y farmacia en línea. El segmento de farmacia hospitalaria dominó el mercado en 2025 con una cuota de 46.67%, debido a la necesidad crítica de compuestos estériles, dispensación controlada y administración hospitalaria de nutrición parenteral y terapias especializadas.
Se espera que el segmento de farmacias especializadas sea testigo del crecimiento más rápido en un CAGR de 8,3% de 2026 a 2033, impulsado por el aumento de la demanda de biológicos, formulaciones nutricionales personalizadas y servicios coordinados de infusión en el hogar.
Asia-Pacífico Tipo 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Tratamiento Mercado Análisis Regional
Japón dominaba el mercado de tratamiento de tipo Asia-Pacífico 1 SBS-IF (síndrome de intestino corto con insuficiencia intestinal), lo que representaba la mayor proporción de ingresos del 23,14% en 2025, debido a su infraestructura de salud avanzada, altas tasas de diagnóstico, fuerte adopción de terapias especializadas y políticas de reembolso de apoyo para trastornos gastrointestinales raros.
Japón Tipo 1 SBS-IF (síndrome de intestino corto con insuficiencia intestinal) tratamiento Mercado Insight
Japón domina el mercado de tratamiento tipo 1 SBS-IF de Asia-Pacífico debido a su infraestructura sanitaria avanzada, sólido marco de reembolso y disponibilidad generalizada de atención gastroenterológica especializada. El país se beneficia de altas tasas de diagnóstico, intervención temprana del tratamiento y amplia adopción de nutrición parenteral avanzada y terapias de apoyo para la gestión del fracaso intestinal. Además, las inversiones continuas en investigación de enfermedades raras, la presencia de las principales empresas farmacéuticas y el creciente interés en la atención de pacientes a largo plazo contribuyen al crecimiento sostenido del mercado y refuerzan la posición de liderazgo de Japón en el mercado regional.
China Tipo 1 SBS-IF (síndrome de intestino corto con insuficiencia intestinal) tratamiento Mercado Insight
China está presenciando un crecimiento significativo en el mercado de tratamiento Tipo 1 SBS-IF, impulsado por la expansión de la infraestructura sanitaria, el aumento del gasto sanitario y el aumento de la conciencia de los trastornos gastrointestinales raros. Las iniciativas gubernamentales que apoyan la gestión de enfermedades raras, junto con la mejora del acceso a instalaciones médicas avanzadas y terapias de apoyo nutricional, están mejorando la disponibilidad de tratamiento en todo el país. Además, se espera que las inversiones crecientes de las empresas farmacéuticas y las mejoras en la capacidad de diagnóstico aceleren la expansión del mercado en los próximos años.
Corea del Sur Tipo 1 SBS-IF (síndrome de intestino corto con insuficiencia intestinal) tratamiento Mercado Insight
El mercado de tratamiento SBS-IF de Corea del Sur cuenta con el apoyo de un sistema sanitario altamente desarrollado, un fuerte apoyo gubernamental para el tratamiento de enfermedades raras y una rápida adopción de tecnologías médicas innovadoras. El énfasis del país en medicina de precisión, atención gastrointestinal especializada y soluciones avanzadas de gestión nutricional ha mejorado los resultados de tratamiento para pacientes SBS-IF. Se espera que las inversiones continuas en investigación médica y la creciente disponibilidad de nuevas terapias fortalezcan aún más el crecimiento del mercado y apoyen el desarrollo de programas integrales de atención al paciente.
India Tipo 1 SBS-IF (síndrome de intestino corto con insuficiencia intestinal) tratamiento Mercado Insight
La India está surgiendo como un creciente mercado para el tratamiento tipo 1 SBS-IF debido a las mejoras en la infraestructura sanitaria, la sensibilización de los trastornos intestinales y la ampliación del acceso a servicios de atención de salud especializados. El crecimiento de hospitales multiespecialistas, mayor disponibilidad de productos de nutrición clínica y el aumento del gasto sanitario están apoyando la adopción de soluciones de tratamiento SBS-IF. Además, se espera que cada vez se centre más en el diagnóstico y la gestión de enfermedades raras, junto con una cobertura más amplia del seguro médico, crear nuevas oportunidades para el crecimiento del mercado en todo el país.
Singapur tipo 1 Sbs-If (Síndrome del intestino delgado con falla intestinal)
El mercado de tratamiento SBS-IF de Singapur está impulsado por su sistema de salud avanzado, un fuerte énfasis en la innovación médica y una creciente demanda de terapias de enfermedades raras especializadas. La infraestructura sanitaria bien establecida del país, los profesionales médicos altamente cualificados y el acceso a opciones de tratamiento de vanguardia apoyan la gestión eficaz de las condiciones de fracaso intestinal. Como centro regional de salud, Singapur también se beneficia de las actividades de investigación clínica en curso, las inversiones farmacéuticas y la adopción creciente de enfoques de tratamiento personalizado, que siguen impulsando el desarrollo del mercado.
Asia-Pacífico Tipo 1 SBS-IF (Short Bowel Syndrome with Intestinal Failure) Tratamiento Mercado Share
El tipo 1 SBS-IF (síndrome de intestino corto con insuficiencia intestinal) industria del tratamiento está dirigido principalmente por empresas bien establecidas, incluyendo:
- Stanford Health Care (Estados Unidos)
- Hospira (Estados Unidos, ahora parte de Pfizer)
- Aurora Health Care (U.S.)
- Takeda Pharmaceutical Company Limited (Japón)
- Fresenius Kabi AG (Alemania)
- Grifols (España)
- Abbott Laboratories (U.S.)
- Shandong Qidu Pharmaceutical Co., Ltd. (China)
- Ferring Pharmaceuticals (Suiza)
- UF Health (Universidad de Florida Health) (Estados Unidos)
- Baxter International (Estados Unidos)
- VectivBio AG (Suiza)
- Farmacéuticos de Ironwood (Estados Unidos)
- Hikma Pharmaceuticals PLC (Jordania)
- Nutricia (Países Bajos)
- Amsino International, Inc. (U.S.)
- Braun Melsungen AG (Alemania)
- ContinuumRx (U.S.)
- Jedux Parenteral Private Limited (India)
- Beverly Hills Digestive Care (Estados Unidos)
- Elección de la Nutrición Parenteral LLC (U.S.)
- Integrated Care Systems (U.S.)
- Camvitaa (No verificado públicamente)
- Eclipse Regenesis (No verificado públicamente)
- Laboratoire Dielen (Francia)
- Vision Parenteral Pvt. Ltd. (India)
- Aculife Healthcare (India)
- Nutrego (No verificado públicamente)
- Pharmko, Inc. (U.S.)
- Infusion Solutions (U.S.)
- NUTRICIA North America (U.S.)
- Terapéutica Napo (Italia)
- Moog Inc. (U.S.)
- ICU Medical, Inc. (Estados Unidos)
- Puerto Life Sciences Pvt. Ltd (India)
- Bausch Health Companies (Canadá)
Últimos desarrollos en Asia-Pacífico Tipo 1 SBS-IF (Síndrome del intestino corto con falla intestinal) TratamientoMercado
- En enero de 2026, Fresenius Kabi ha introducido una nueva forma de dosificación de su ustekinumab biosimilar (Otulfi), que ofrece un vial de dosis única de 45 mg/0,5 mL. Esta adición amplía el rango de presentación disponible de Otulfi, que es un biosimilar a Stelara de Janssen (ustekinumab). Con esta actualización, Fresenius Kabi proporciona ahora múltiples formas de dosis y fortalezas del producto de referencia, mejorando la flexibilidad para los médicos y opciones de tratamiento para los pacientes. Esto fortalece la cartera biosimilar de Fresenius Kabi mejorando la flexibilidad del producto.
- En marzo de 2026, Baxter International ha introducido el IV Verify Line Labeling System, una solución automatizada diseñada para reemplazar etiquetas IV manuscritas con etiquetado estandarizado y basado en códigos de barras en hospitales. El sistema ayuda a los clínicos a imprimir etiquetas adhesivas claras y codificadas por colores para el tubo IV, mejorando la precisión y reduciendo errores de medicamentos en la parte posterior. Fortalece la posición de Baxter en la tecnología de infusión hospitalaria.
- En febrero de 2026, Nestlé Health Science anunció la inclusión de sus productos nutricionales en un marco de reembolso excepcional dentro del sistema de salud pública de Portugal, permitiendo que los productos elegibles sean cubiertos parcialmente o totalmente por el Servicio Nacional de Salud. Esta decisión regulatoria refuerza el acceso de los pacientes a soluciones de nutrición clínica y apoya la integración de la nutrición médica en vías formales de reembolso de salud. Esto beneficiará a la empresa mejorando la accesibilidad de los productos, ampliando la demanda basada en recetas y reforzando su posición dentro del mercado clínico de nutrición reembolsado.
- En 2025, Abbott amplió sus líneas de productos nutricionales de Asegurar y Glucerna en 2025, introduciendo formulaciones mejoradas con contenido de proteínas mejorado, mejor gusto y formatos adicionales de productos como batidos listos para beber y opciones de nutrición basadas en aperitivos. La expansión tiene como objetivo apoyar la salud muscular, la gestión de la diabetes, el envejecimiento de la población y las necesidades de nutrición clínica en los centros hospitalarios y de atención a domicilio.
- In May 2024, Moog Inc. received FDA 510(k) clearance for its CURLIN 8000 Ambulatory Infusion System, a next-generation platform designed for advanced home infusion therapy. El sistema está diseñado para ofrecer múltiples terapias con mayor precisión, seguridad y flexibilidad en entornos ambulatorios y de cuidado en el hogar. Mejora la administración precisa de medicamentos y nutrientes, lo que lo hace muy adecuado para los pacientes que requieren apoyo nutricional parenteral a largo plazo. En el contexto del Síndrome de Tazón Corto con Failure Intestinal (SBS-IF), donde los pacientes dependen a menudo de la nutrición parenteral doméstica (HPN), la CURLIN 8000 desempeña un importante papel de apoyo.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCCIÓN
1.1 OBJETIVOS DEL ESTUDIO
1.2 DEFINICIÓN DEL MERCADO
1.3 Revisión general del TYPE ASIA-PACIFIC 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITACIONES
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 ÁMBIÉN GEOGRÁFICO
2.3 AÑOS ESTUDIOS PARA EL ESTUDIO
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 ENTREVISTAS PRIMARÍAS CON LEADRES DE OPINION KEY
2.6 GRID DE POSICIÓN DEL MERCADO
2.7 VENDOR SHARE ANALISIS
2.8 MULTIVARIATE MODELING
2.9 CURVE DE TIPO DE PRODUCTOS
2.1 MARKET APPLICATION GRID
2.11 FUERZAS SEGUNDARIAS
2.12 ASUNTOS
RESUMEN EJECUTIVO
4 fotos INSIGHTS
4.1 ANÁLISIS PESTEL
4.1.1 INTRODUCCIÓN
4.1.2 ANÁLISIS POLÍTICO
4.1.3 ANÁLISIS ECONÓMICO
4.1.4 ANÁLISIS SOCIAL
4.1.5 ANÁLISIS TECNOLOGICO
4.1.6 ANÁLISIS AMBIENTE
4.1.7 ANÁLISIS JURÍDICO
4.1.8 CONCLUSIÓN
4.2 FIVE FORCES DE PORTER
4.2.1 INTRODUCCIÓN
4.2.2 INTENSITY OF COMPETITIVE RIVALRY (HIGH)
4.2.3 POWER BARGAINING POWER OF BUYERS – ALTO
4.2.4 Tres de los nuevos territorios - MODERATE
4.2.5 THREAT OF SUBSTITUTE PRODUCTS – MODERATE
4.2.6 BARGAINING POWER OF SUPPLIERS – MODERATE
4.2.7
4.3 QUADRANT DE EVALUACIÓN DE EMPRESAS
4.4 METODOLOGÍA DEL FONDO PACTO (MODEL DE MANDATORIA)
4.4.1 Un FONDO PACIENTE DE BOTTOM-UP será CONSTRUCIDO
4.4.1.1 POBLACIÓN TOTAL DE SBS
4.4.1.2 POBLACIÓN SBS-IF
4.4.1.3 DIAGNOSED SBS-IF PATIENTS
4.4.1.4 PACIENTES TREATED SBS-IF
4.4.1.5 POOLAS PACIENTES THERAPY-SPECIFIC
4.4.1.6 ESTE ENSURES PATIENT NUMBERS are DIRECTLY ESTIMATED, NO INFERREDED from MARKET SIZE
4.4.1.7 ASIA-PACIFIC PATIENT FUNNEL SEGMENTATION
4.4.1.8 POBLACIÓN TOTAL DE SBS
4.4.1.9 SBS ADULT
4.4.1.10 PEDIATRIC SBS
4.4.1.11 POBLACIÓN SBS-IF
4.4.1.12 TYPE 1 SBS-IF (ACUTE)
4.4.1.13 TYPE 2 SBS-IF (PROLONGED ACUTE)
4.4.1.14 TYPE 3 SBS-IF (CHRONIC)
4.4.1.15 POBLACIÓN DIAGNOSADA
4.4.1.16 DIAGNOSED – HOSPITAL-BASED
4.4.1.17 DIAGNOSED – OUTPATIENT
4.4.1.18 UNDIAGNOSED / MISCLASSIFIED
4.4.1.19 POBLACIÓN PACIENTE TREATED
4.4.1.20 PACIENTES TREATEDES
4.4.1.21
4.4.2 TREATMENT-SPECIFIC PATIENT SEGMENTATION (CRITICAL)
4.4.2.1 POPULACIÓN PACIENTE PN-DEPENDIENTO (SEGMENTO DE CORE)
4.4.2.2 FULLY PN-DEPENDENT
4.4.2.3 PARTIALLY PN-DEPENDENT
4.4.2.4 UCI PN-DEPENDENT (TYPE 1 ACUTE)
4.4.2.5 HOME PN-DEPENDENT
4.4.2.6 GLP-2 ANALOGUE TREATED PATIENTS
4.4.2.7 INCLUYEN LOS PACIENTES RECIBIDAS
4.4.2.8 PIPELINE THERAPIES (E.G., APRAGLUTIDE)
4.4.2.9
GLP-2
4.4.2.11 PN-WEANING PATIENTS
4.4.2.12 PEDIATRIC VS ADULT
4.4.2.13 PHARMACOTHERAPY PATIENTS (ATTRIBUTABLE)
4.4.2.14 USUARIOS ANTI-DIARRHEAL
4.4.2.15
4.4.2.16 ANTIBIOTIC (SIBO) PACIENTES
4.4.2.17 MICRONUTRIENT-DEPENDENT PATIENTS
4.4.2.18 PACIENTES SURGICOS Y TRANSPLANTES
4.4.2.19 PROCEDIMIENTOS DE LENGTHENAL
4.4.2.20 PACIENTES TRANSPLANTES
4.4.2.21 SURVIVORS POST-TRANSPLANT
4.4.3 SEGMENTACIÓN PACIENTE POR DEPENDENCY STATUS (HIGHLY IMPORTANT)
POPULACIÓN PN-DEPENDIEN
4.4.3.2 SEGUIMIENTO DE LA REVENCIÓN DE LOS PAÍSES
4.4.3.3 POPULACIÓN DE PNBANING
4.4.3.4 RESPONDERS GLP-2
POPULACIÓN PN-INDEPENDENT
4.4.3.6 MAINTAINED ON ORAL/ENTERAL THERAPY
4.4.4 SEGMENTACIÓN PACIENTE POR FASE DISEÑO (TYPE 1 FOCUS)
4.4.4.1 ACUTE PHASE (TYPE 1 SBS-IF)
4.4.4.2 ICU-MANAGED PATIENTS
4.4.4.3 HIGH PN UTILIZATION
4.4.4.4 FASE DE ADAPTACIÓN
4.4.4.5 TRANSICIÓN A LA NUTRICIÓN ENTERAL
4.4.4.6 INITIATION OF GLP-2 THERAPY
4.4.4.7 HABILIZACIÓN / ESTABILIZACIÓN
4.4.4.8 REDUCED PN DEPENDENCY
4.4.4.9 MANTENIMIENTO DE LOS TERMINOS
4.4.4.10 SEGMENTACIÓN PACIENTE POR CARE
4.4.4.11 PACIENTES HOSPITAL-BASED
4.4.4.12 UCID
4.4.4.13 WARDS SURGICAS
4.4.4.14 PACIENTES DE CARE
4.4.4.15 HOME PARENTERAL NUTRITION (HPN)
4.4.16 CENTROS ESPECIALES
4.4.4.17 CENTROS INTESTINALES DE REHABILITACIÓN
4.4.5 SEGMENTACIÓN PACIENTE POR LOS DEMOGRAFÍAS
4.4.5.1 GRUPO DE AGE
4.4.5.2 NEONACIONES
4.4.5.3 PEDIATRIC
4.4.5.4
4.4.5.5 GERIATRIC
4.4.5.6 GENDER
4.4.5.7
4.4.5.8 FEMALE
4.4.6 SEGMENTACIÓN PACIENTE POR ETIOLOGÍA
4.4.6.1 ETIOLOGÍA ADULT
4.4.6.2 DISEÑO DE CROHN
4.4.6.3 MESENTERIC ISCHEMIA
4.4.6.4 Respuestas SURGICAS
4.4.6.5 REALIZADO DE LAS NACIONES UNIDAS
4.4.6.6 ETIOLOGÍA PEDIATRIC
4.4.6.7 NECROTIZING ENTEROCOLITIS (NEC)
4.4.6.8 DEFECTOS CONGENIALES (ATRESIA, GASTROSCHISIS)
4.4.7 DISTRIBUCIÓN PACIENTE GEOGRÁFICO
4.4.7.1 NORTH AMERICA
4.4.7.2 U.S.
4.4.7.3 CANADA
4.4.7.4 EUROPA
4.4.7.5 ALEMANIA
4.4.7.6
4.4.7.7 Reino Unido
4.4.7.8
4.4.7.9 ESPAÑA
4.4.7.10 ASIA-PAIFIC
4.4.7.11 JAPÓN
4.4.7.12 CHINA
4.4.7.13 INDIA
4.4.8 TREATMENT PENETRATION " UTILIZATION RATES
4.4.8.1 PN PENETRATION RATE
4.4.8.2 % DE PACIENTES SBS-IF EN PN
4.4.8.3 GLP-2
4.4.8.4 % DE LOS PACIENTES ELIGIBLES GLP-2
4.4.8.5 Perfeccionamiento de la Terapia
4.4.8.6 ANTI-DIARRHEAL USAGE RATE
4.4.8.7 PPI USAGE RATE
4.4.8.8 Modificación de los GASTOS PATIENT-LEVEL
4.4.8.9 Gastos anuales
4.4.8.10 PN COST (HOSPITAL VS HOME)
4.4.8.11 GLP-2 THERAPY COST
4.4.8.12 GASTOS DE ARAPACIDAD
4.4.9 COST BY PATIENT TYPE
4.4.9.1 PN-DEPENDENT
4.4.9.2 GLP-2
4.4.9.3
4.4.9.4 DELIVERABLES DELPUT (EXCEL – CLIENT CRITICAL)
4.4.9.5 PACIENTES TOTAL SBS-IF (Por país)
4.4.9.6 VS DIAGNOSED TREATED PATIENTS
4.4.9.7 PN-DEPENDENT PATIENTS
4.4.9.8 GLP-2 TREATED PATIENTS
4.4.9.
4.4.9.10 AVERAGE ANNUAL COST PER THERAPY
4.5 INSIGHTS INDUSTRY
4.5.1 INTRODUCCIÓN
4.5.2 Examen general de la estructura interna
4.5.3 MICRO Y FACTORES ECONÓMICOS MACRO
4.5.4 PENETRATION AND GROWTH PROSPECT MAPPING
4.5.5 ESTRATEGIAS PRINCIPALES
4.5.6 INTERVIEWS with SPECIALISTS
4.5.7 ANÁLISIS Y RECOMENDACIÓN
4.5.8 CONCLUSIÓN
4.6 LA DISRUPCIÓN DE LA GUERRA DE LA GUERRA DE LOS CHAINS PHARMACEUTICAS SUPPLY, GEOGRAPHIC FOOTPRINTs, STRUCTURAL CHANGES, AND ADAPTIVE STRATEGIES
INTRODUCCIÓN
4.6.2 RESULTIVAMENTE CHAIN
4.6.2.1 DIVERSIFICACIÓN DE LOS SUPLEMENTOS INGRESOS Y PN/DRUG
4.6.2.2 ESTABLECIMIENTO DE LOS HUBES DE PRODUCCIÓN REGIONAL
STRATEGIC STOCKPILING OF CRITICAL PN BAGS, GLP-2 ANALOGUES, AND MEDICAL DEVICES
4.6.2.4 DESARROLLO DE LAS LOGISTICAS ALTERNATIVAS Y LOS CHAINES COLOS
4.6.2.5 CENTROS ESTRATEGICOS CON CDMOS LEADING (E.G., CATALENT, LONZA)
4.6.2.6 EXPANSION OF MANUFACTURING, FILL-FINISH, AND PACKAGING CAPABILITIES FOR PN & GLP-2
4.6.3 ENERGÍA " MANUFACTURING OPERATIONAL COST RISK
4.6.3.1 RISING ENERGY COSTS IN PARENTERAL NUTRITION ' DRUG FACILITIES
4.6.3.2 GASTOS INCREADOS PARA MATERIALES RAW, EMULSIONES LIPID, Y PHARMACEUTICAS
4.6.3.3 ESTRATEGIAS DE PROCURACIÓN DE LA ENERGÍA ENTRE LOS PN MANUFACTURERES
4.6.3.4 APROBACIÓN DE LAS TECNOLOGÍAS DE MANUFACTURACIÓN DE ENERGÍAS
4.6.3.5 DEPLOYMENT OF ADVANCED AUTOMATION AND CONTINUOUS SYSTEMS
4.6.3.6 INTEGRACIÓN DE LA ENERGÍA RENEWABLE EN LAS FACILIDADES DE MANUFACTURACIÓN
4.6.4 Observaciones de la FOOTPRINT GEOGRAPHIC
4.6.4.1 EXPANSION OF MANUFACTURING IN STABLE REGIONS
4.6.4.2 DIVERSIFICACIÓN DE PN/GLP-2 ASIA-PACIFIC
4.6.4.3 RELOCACIÓN DE LA PRODUCCIÓN DE KEY INPUT/INTERMEDIATE
4.6.4.4 EXPANSION INTO EMERGING MARKETS with HIGH SBS-IF BURDEN
4.6.4.5 ESTABLECIMIENTO DE LOS HUBOS DE TRANSICIÓN Y DISTRIBUCIÓN REGIONALES
4.6.5 Plantilla SCENARIO " RISK MANAGEMENT
4.6.5.1 DESARROLLO DE PLANES DE CONTINGENCY SUPLEMENTE
4.6.5.2 ESTRATEGIAS DE PROCURACIÓN MULTI-SOURCE PARA PN/GLP-2
4.6.5.3 COLABORACIONES DE GOBIERNO Y SALUD
4.6.5.4 Redes de respuesta de la crisis para las terapias críticas
4.6.5.5 DEPLOYMENT OF PREDICTIVE SUPPLY CHAIN ANALYTICS IN SBS-IF MARKET
4.6.6 CASH " FINANCIERA PROTECCIÓN
4.6.7 RESERVAS DE CAPITAL PARA LA EXPANSIÓN PN " BIOPHARMA
4.6.7.1 DIVERSIFICACIÓN DE LOS PORFOLIOS DE PRODUCTOS Y LAS ESFERAS REVENIDAS
4.6.7.2 INVESTMENTOS EN LA INFRASTRUCTURA DE LA PRODUCCIÓN DOMESTICA
4.6.7.3 INSTITUCIONES DE GOBIERNO Y PARTE PUBLIC-PRIVATE
4.6.7.4 LONG-TERM PROCUREMENT CONTRACTS with HEALTHCARE SYSTEMS
4.6.8 Protección de datos
4.6.8.1 MARCOS DE PROTECCIÓN DE DATOS PARA LOS DATOS CLINICOS Y REALES
4.6.8.2 PROTECCIÓN DE DATOS TRIALES CLINICOS, DATOS PACIENTES Y DESARROLLO DE DROGAS
4.6.8.3 SECURE CLOUD INFRASTRUCTURE FOR SBS-IF DATA MANAGEMENT
4.6.8.4 INTRODUCCIÓN DE LA TERCERA DETECCIÓN DE LA INVESTIGACIÓN Y LAS REDES DE PHARMA
4.6.8.5 CUMPLIMIENTO DE LAS REGULACIONES DE DATOS PHARMACEUTICAS " GXP
4.6.9 NUEVA BUSINESS AND EMERGING REVENUE OPPORTUNITIES " FUTURE OUTLOOK
4.6.10 Conclusión
4.7 EPIDEMIOLOGY
INTRODUCCIÓN
4.7.2 INCIDENCE OF TYPE 1 SBS-IF BY GENDER
4.7.3 TREATMENT RATE
4.7.4 MORTALITY RATE
4.7.5 TREATMENT ADHERENCE AND SWITCH MODEL
4.7.6 TREATMENTO DE TRATAMIENTO
4.7.7 Conclusión
4.8 DISTRIBUCIÓN DE PRODUCTOS Y PROYECTOS POR FASE ASIA-PACIFIC TYPE 1 SBS-IF MARKET
4.9 DISTRIBUCIÓN DE LOS PROYECTOS POR APPROACH CIENTÍFICO Y FASE – ASIA-PACIFIC TYPE 1 SBS-IF MARKET
4.1 DISTRIBUCIÓN DE LOS PROYECTOS POR EL AREA Y LA FASE THERAPEUTIC TYPE 1 SBS-IF MARKET
4.11 ANÁLISIS PIPELINA
INTRODUCCIÓN
4.11.2 TRIALS CLINICAL AND PHASE ANALYSIS
4.11.3 PIPELINA DE DROGAS
4.11.4 PHASE III CANDIDATES (E.G., APRAGLUTIDE)
4.11.5 PHASE II CANDIDATES (E.G., LONG-ACTING GLP-2)
4.11.6 FASE I CANDIDATES (EMERGING REGENERATIVE/CELLULAR)
4.11.7 OTHERS (PRE-CLINICAL, EN FORMULATION PIPELINE)
4.11.8 CONCLUSIÓN
4.12 ANÁLISIS PIPELINA
INTRODUCCIÓN
4.12.2 EMPRESA DE LA PHARMACEUTICA DE TAKEDA – LÍADERSHIP DE LA REGENERACIÓN INTESTINAL
4.12.3 BAXTER INTERNATIONAL – PARENTERAL NUTRITION AND INFUSION SYSTEM INNOVATION
4.12.4 FRESENIUS KABI AG – LA NUTRICIÓN CLINICA Y EL DESARROLLO DE LA THERAPY INJECTABLE
4.12.5 NESTLÉ HEALTH SCIENCE – MEDICAL NUTRITION AND GUT ADAPTATION RESEARCH
4.12.6 LABORATORES ABBOTT – INTEGRATED NUTRITION AND METABOLIC MONITORING SOLUTIONS
4.12.7
4.13 ANÁLISIS DE THERAPY MARKETED
INTRODUCCIÓN
4.13.2 DRUG/THERAPY
4.13.2.1 MARCO
4.13.2.2 Nombre de los GENERICES
4.13.3 CLASIFICACIÓN PHARMACOLOGICA
4.13.4 INDICACIÓN PRIMARIA
4.13.5 MARKET STATUS
4.13.6 Medios de acción
4.13.7
4.13.8 DISPONIBILIDAD
4.13.9 PACKAGING TYPE
4.13.10 ROUTE OF ADMINISTRATION
4.13.11 FRECUENCIA DE DOS
4.13.12 INSIGHT
4.13 Una visión general de las actividades de desarrollo de la sequía, las miles de carácter reglamentario, la seguridad y la administración, los datos sobre la exclusividad del mercado
4.13.14 FORECAST MARKET OUTLOOK
4.13.14.1 CROSS COMPETITION
4.13.14.2 THERAPEUTIC PORTFOLIO
4.13.14.3 CURRENT DEVELOPMENT SCENARIO
4.13.15
4.14 ANALISIS PIPELINA - ASIA-PACIFIC TYPE 1 MERCADO DE TRATAMIENTO SBS-IF
4.14.1 TRIALS CLINICAL AND PHASE ANALYSIS
4.14.2 PIPELINA DE DROGAS Y BIOTHERAPY
4.14.3 PHASE III CANDIDATES
4.14.4 PHASE II CANDIDATES
4.14.5 PHASE I CANDIDATES
4.14.6 OTHERS (PRE-CLINICAL AND RESEARCH STAGE)
4.15 R ' D ANALYSIS
ANÁLISIS COMPARATIVO
4.15.2 LANDSCAPE PARA EL DESARROLLO
4.15.3 INSIGHTS ON REGULATORY MILESTONES
4.15.4 Asistencia técnica
4.15.5 COLABORACIONES Y PARTICIPACIONES DE ASISTENCIA
5 HEALTHCARE TARIFFS IMPACT ANALYSIS
5.1 Examen general
5.2 ESTRUCTURAS DE TARIFF
5.2.1 ESTRUCTURAS ASIA-PACIFICAS
5.2.2 ESTADOS UNIDOS: MEDICARE/MEDICAID TARIFF POLICIES
5.2.3 ASIA-PACIFIC: GOVERNMENT TARIFFS ON IMPORTED PN/DRUG THERAPIES
5.2.4 MARKETS EMERGING: TARIFF CHALLENGES FOR NUTRITION " BIOLOGICS
5.2.5 MAJOR MARKET UPTAKE
5.3 TARIFAS PHARMACEUTICAS Y BARRIERS TRADE
5.3.1 IMPORT DUTIES ON PN KITS, GLP-2 VS. GENERICS
5.3.2 IMPACT ON AFFORDABILITY " ACCESS
5.3.3 ACUERDOS DE COMERCIO DE KEY AFECTANDO PRODUCTOS SBS-IF
5.4 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS/PATIENTS
5.4.1 COST BURDEN ON HOSPITALS AND FACILITIES
5.4.2 EFECTO SOBRE LA AFFORDABILIDAD PACIENTE
5.4.3 HABITACIÓN EN EL TOURISMO MEDICAL PARA LAS ARMAS DE SBS-IF
5.5 ACUERDOS DE COMERCIO Y ACTIVIDADES DE SALUD
5.5.1 REGULACIONES DE LA OMC
5.5.2 EJECUCIÓN DE AGUAS COMERCIALES EN EL CAPÍTULO
5.5.3 FTAS IN REDUCING TARIFFS
5.6 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY
5.7 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR
6 MARKET ACCESS
6.1 10 años de duración
6.2 Subsidios regionales
6.3 APROBACIONES NUEVAS DEL FDA ANUAL PARA LOS TRATAMIENTOS SBS-IF
6.4 MANUFACTURES, DISTRIBUTORS, AND DEALS
6.5 MAJOR MARKET UPTAKE
6.6 PRÁCTICAS DE TRATAMIENTO ACTUAL
6.7 IMPACT OF UPCOMING THERAPIES
7 MARCO REGULATORIO –
7.1 INTRODUCCIÓN
7.2 PROCESO DE APROBACIÓN REGULATORIA
7.3 EASE of REGULATORY APPROVAL
7.4 PATHWAYS DE APROBACIÓN REGULATORIA
7.5 LICENCIA Y REGISTRACIÓN
7.6 POST-MARKEILLANCE
7.7 Guías de buenas prácticas de manipulación
7.8 CONCLUSIÓN
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISING SBS-IF PATIENT POPULATION
8.1.2 APROBACIÓN DE LA APROBACIÓN DE LAS ARMAS GLP-2
8.1.3 INCREASING GOVERNMENT " ORPHAN DRUG SUPPORT
8.2 RESTRAINTS
8.2.1 GASTOS DE SBS-IF
8.2.2 LIMITE.D AWARENESS & DELAYED DIAGNOSIS
8.3 OPORTUNIDADES
8.3.1 GESTIÓN DE LOS PACIENTES MULTIDISCIPLINARIOS
8.3.2 PROCESOS DE APROBACIÓN REGULATORIA ESTUDIANTE
8.4
8.4.1 AVANCES IN REGENERATIVE MEDICINE
8.4.2 EXPANSION OF HOME-BASED NUTRITIONAL CARE
9 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY
9.1 Examen general
9.2 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
9.2.1 NUTRITIONAL SUPPORT THERAPY
9.2.2 Terapia PHARMACOLOGICA
9.2.3 TREATMENTO SURGICO e INTERVENTIONAL
9.2.4 EMERGING " ADVANCED THERAPIES
9.3 ASIA-PACIFIC NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.3.1 PARENTERAL NUTRITION (PN)
9.3.2 ENTERAL NUTRITION (EN)
9.3.3 PN COMPOSITION
9.4 ASIA-PACIFIC PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SYNDROME BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.4.1 HOME PARENTERAL NUTRITION (HPN)
9.4.2 LA NUTRICIÓN PARENTERAL PERIPHERAL (PPN)
9.4.3 ADPIC PARENTERAL
9.5 ASIA-PACIFIC TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.5.1 TPN HOSPITAL-BASED
9.5.2 PT PNB
9.6 ASIA-PACIFIC HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
9.6.1 HPN ADULT
9.6.2 PEDIATRIC HPN
9.7 ASIA-PACIFIC HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
9.7.1 HPN LONG-TERM
9.7.2 HPN SHORT-TERM
9.8 ASIA-PACIFIC ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.8.1 FEEDING ORAL
9.8.2 TUBE FEEDING
9.8.3 FORMULA TYPE
9.9 ASIA-PACIFIC TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.9.1 NASOGASTRIC (NG)
9.9.2 PEG FEEDING
9.9.3 JEJUNOSTOMY FEEDING
9.1 ASIA-PACIFIC FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.10.1 POLYMERIC
9.10.2 ELEMENTAL
9.10.3 SEMI-ELEMENTAL
9.11 COMPOSICIÓN PN ASIA-PACIFIC EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.11.1 MACRONUTRIENTS
9.11.2 ELECTROLYTES " FLUIDS
9.11.3 MICRONUTRIENTS
9.12 ASIA-PACIFIC MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.12.1 AMINO ACIDS
9.12.2 EMULSIONES LIPID
9.12.3 DEXTROSE
9.13 MICRONUTRIENTS ASIA-PACIFIC EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.13.1 VITAMINS
9.13.2 ELEMENTOS DE TRABAJO
9.14 ASIA-PACIFIC NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
9.14.1 NORTH AMERICA
9.14.2 EUROPA
9.14.3 ASIA-PACIFIC
9.14.4 ORIENTE MEDIO Y ÁFRICA
9.14.5 SOUTH AMERICA
9.15 THERAPY ASIA-PACIFIC PHARMACOLOGICAL EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.15.1 Terapia de ADAPTACIÓN HORMONAL
9.15.2 Terapia ANTI-DIARHEAL
9.15.3 ANTI-SECRETORY THERAPY
9.15.4 APLICACIÓN MICRONUTRIENTE
9.15.5 THERAPY ANTI-INFECTIVE
9.15.6 BILE ACID " ABSORPTION MODIFIERS
9.16 ASIA-PACIFIC HORMONAL " INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SYNDROME BOWEL con FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.16.1 ANÁLOGO GLP-2
9.16.2 GROWTH HORMONE THERAPY
9.16.3 IGF-1 " ANALOGUES
9.17 ANÁLOGOS ASIA-PACIFICOS GLP-2 EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED THOUSAND)
9.17.1
9.17.2 APRAGLUTIDE (LATE-STAGE)
9.17.3 ANALOGOS GLP-2 DE CUMPLIMIENTO
9.18 ASIA-PACIFIC GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)
9.18.1 HUMATROPE
9.18.2 NORDITROPIN
9.18.3 GENOTROPIN
9.19 ASIA-PACIFIC IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.19.1 INCRELEX
9.19.2 OTROS
9.2 ASIA-PACIFIC ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.20.1 OPIOID-BASED
9.20.2 ORGANIZACIONES NO ORGANIZADAS
9.21 ASIA-PACIFIC OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.21.1 LOPERAMIDE
9.21.2 CODEINA
9.22 THERAPY ASIA-PACIFIC ANTI-SECRETORY IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.22.1 INHIBITORES DE PUMP PROTON
9.22.2 ANÁLOGOS SOMATOSTATALES
9.22.3 H2 RECEPTOR ANTAGONISTAS
9.23 INHIBITORES DE PROTONES ASIA-PACIFICOS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
9.23.1 OMEPRAZOLE
9.23.2 PANTOPRAZOLE
9.23.3 ESOMEPRAZOLE
9.23.4 OTROS
9.24 ANÁLOGOS SOMATOSTATALES ASIA-PACIFICOS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (US$ THOUSAND)
9.24.1 OCTREOTIDE
9.24.2 OTROS
9.25 ASIA-PACIFIC H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.25.1 FAMOTIDINE
9.25.2 OTROS
9.26 ASIA-PACIFIC MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.26.1 VITAMINAS FAT-SOLUBLE (A, D, E, K)
9.26.2 ELECTROLYTES
9.26.3 VITAMIN B12
9.26.4 APLICACIÓN MINERAL
9.27 ASIA-PACIFIC ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.27.1 ANTÍTICOS BROAD-SPECTRUM
9.27.2 THERAPY
9.28 MODIFICIOS DE ACID DE BILA ASIA-PACIFICA " ABSORPTION en TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.28.1 BILE ACID SEQUESTRANTS
9.28.2 FAT ABSORPTION ENHANCERS
9.29 ASIA-PACIFIC BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.29.1
9.29.2 COLESEVELAM
9.29.3 Otros
9.3 ASIA-PACIFIC PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
9.30.1 NORTH AMERICA
9.30.2 EUROPA
9.30.3 ASIA-PACIFIC
9.30.4 ORIENTE MEDIO Y ÁFRICA
9.30.5 SOUTH AMERICA
9.31 ASIA-PACIFIC SURGICAL " INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.31.1 PROCEDIMIENTOS DE LA LENGTHENAL
9.31.2 OSTOMÍA " RECONSTRUCCIÓN "
9.31.3 TRANSPLANTACIÓN INTESTINAL
9.32 ASIA-PACIFIC INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.32.1
9.32.2 BIANCHI PROCEDURE
9.33 ASIA-PACIFIC OSTOMY " RECONSTRUCTION IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.33.1
9.33.2 JEJUNOSTOMY
9.33.3 REVERSAL SURGERY
9.34 TRANSPLANTACIÓN INTESTINAL ASIA-PACIFIC EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.34.1 CENTRO SMALL ISOLATED
9.34.2 LIVER + INTESTINE
9.34.3 TRANSPLANT MULTIVISCERAL
9.35 ASIA-PACIFIC SURGICAL " INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
9.35.1 NORTH AMERICA
9.35.2 EUROPA
9.35.3 ASIA-PACIFIC
9.35.4 ORIENTE MEDIO Y ÁFRICA
9.35.5 SOUTH AMERICA
9.36 Terapias Asia-PACIFIC EMERGING " AVANCED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.36.1 MEDICINA
9.36.2 Terapia de apoyo a la MICROBIOME
9.36.3 GENE THERAPY
9.37 MEDICINA REGENERATIVO ASIA-PACIFIC EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.37.1
9.37.2 INTESTINA TISSUE-ENGINEERED
9.38 ASIA-PACIFIC MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.38.1
9.38.2 FMT
9.39 ASIA-PACIFIC GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
9.39.1 Inicio de la FUNCIÓN ABSORPTIVE
9.39.2 MUCOSAL GROWTH MODULATION
9.4 EMERGACION ASIA-PACIFICA " AVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
9.40.1 NORTH AMERICA
9.40.2 EUROPA
9.40.3 ASIA-PACIFIC
9.40,4 MIDDLE EAST AND AFRICA
9.40.5 SOUTH AMERICA
10 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION
10.1 Examen general
10.2 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
10.2.1 CORE SBS-IF MARKET
10.2.2 SBS-IF
10.2.3 ADJACENT / NON-SPECIFIC MARKET
10.3 ASIA-PACIFIC CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
10.3.1 PARENTERAL NUTRITION
10.3.2 ANÁLOGO GLP-2
10.4 ASIA-PACIFIC CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (US$ THOUSAND)
10.4.1 NORTH AMERICA
10.4.2 EUROPA
10.4.3 ASIA-PACIFIC
10.4.4 EAST MIDDLE Y AFRICA
10.4.5 SOUTH AMERICA
10.5 ASIA-PACIFIC SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
10.5.1 ANTI-DIARRHEALS
10.5.2 PPIS
10.5.3 ANTÍTICOS
10.6 ASIA-PACIFIC SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
10.6.1 NORTH AMERICA
10.6.2 EUROPA
10.6.3 ASIA-PACIFIC
10.6.4 Medio Oriente y ÁFRICA
10.6.5 SOUTH AMERICA
10.7 ASIA-PACIFIC ADJACENT / NON-SPECIFIC MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
10.7.1 NORTH AMERICA
10.7.2 EUROPA
10.7.3 ASIA-PACIFIC
10.7.4 Aire acondicionado y ÁFRICA
10.7.5 SOUTH AMERICA
11 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE
11.1 Examen general
11.2 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
11.2.1 ACUTE PHASE (TYPE 1 SBS-IF)
11.2.2 FASE DE ADAPTACIÓN
11.2.3 FASE RECOVERY
11.3 ASIA-PACIFIC ACUTE PHASE (TYPE 1 SBS-IF) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
11.3.1 NORTH AMERICA
11.3.2 EUROPA
11.3.3 ASIA-PACIFIC
11.3.4 Medio Oriente y ÁFRICA
11.3.5 SOUTH AMERICA
11.4 FASE ASIA-PACIFICA EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
11.4.1 NORTH AMERICA
11.4.2 EUROPA
11.4.3 ASIA-PACIFIC
11.4.4. EAST MIDDLE Y AFRICA
11.4.5 SOUTH AMERICA
11.5 FASE ASIA-PACIFIC RECOVERY EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (US$ THOUSAND)
11.5.1 NORTH AMERICA
11.5.2 EUROPA
11.5.3 ASIA-PACIFIC
11.5.4 Medio Oriente y ÁFRICA
11.5.5 SOUTH AMERICA
12 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE
12.1 Examen general
12.2 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
12.2.1 ADULT
12.2.2 PEDIATRIC
12.3 ASIA-PACIFIC ADULT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
12.3.1 NORTE AMERICA
12.3.2 EUROPA
12.3.3 ASIA-PACIFIC
12.3.4 Aire acondicionado
12.3.5 SOUTH AMERICA
12.4 PEDIATRIC ASIA-PACIFIC EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
12.4.1 NORTH AMERICA
12.4.2 EUROPA
12.4.3 ASIA-PACIFIC
12.4.4. EAST MIDDLE Y AFRICA
12.4.5 SOUTH AMERICA
13 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
13.1 Examen general
13.2 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
13.2.1 INTRAVENCION
13.2.2
13.2.3 ORAL
13.2.4 ENTERAL
13.3 ASIA-PACIFIC INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
13.3.1 PN
13.3.2
13.4 ASIA-PACIFIC INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
13.4.1 NORTE AMERICA
13.4.2 EUROPA
13.4.3 ASIA-PACIFIC
13.4.4 Aire acondicionado y ÁFRICA
13.4.5 SOUTH AMERICA
13.5 ASIA-PACIFIC SUBCUTANEOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
13.5.1 NORTE AMERICA
13.5.2 EUROPA
13.5.3 ASIA-PACIFIC
13.5.4 Medio Oriente y ÁFRICA
13.5.5 SOUTH AMERICA
13.6 ASIA-PACIFIC ORAL IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
13.6.1 NORTE AMERICA
13.6.2 EUROPA
13.6.3 ASIA-PACIFIC
13.6.4 Medio Oriente y ÁFRICA
13.6.5 SOUTH AMERICA
13.7 ASIA-PACIFIC ENTERAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
13.7.1 NORTH AMERICA
13.7.2 EUROPA
13.7.3 ASIA-PACIFIC
13.7.4 Medio Oriente y ÁFRICA
13.7.5 SOUTH AMERICA
14 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER
14.1 Examen general
14.2 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
14.2.1 HOSPITALS (ACUTE CARE)
14.2.2 Home CARE (Programas de HPN)
14.2.3 SETTINGS ICU
14.2.4 CENTROS PECIALTY GI
14.2.5 PEDIATRIC SPECIALTY HOSPITALS
14.3 HOSPITALS ASIA-PACIFIC (ACUTE CARE) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (US$ THOUSAND)
14.3.1 NORTE AMERICA
14.3.2 EUROPA
14.3.3 ASIA-PACIFIC
14.3.4 Medio Oriente y ÁFRICA
14.3.5 SOUTH AMERICA
14.4 ASIA-PACIFIC HOME CARE (HPN PROGRAMS) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
14.4.1 NORTH AMERICA
14.4.2 EUROPA
14.4.3 ASIA-PACIFIC
14.4.4 ORIENTE MEDIO Y ÁFRICA
14.4.5 SOUTH AMERICA
14.5 SETTINGS ASIA-PACIFIC ICU EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
14.5.1 NORTE AMERICA
14.5.2 EUROPA
14.5.3 ASIA-PACIFIC
14.5.4 Medio Oriente y ÁFRICA
14.5.5 SOUTH AMERICA
14.6 ASIA-PACIFIC SPECIALTY GI CENTROS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (US$ THOUSAND)
14.6.1 NORTE AMERICA
14.6.2 EUROPA
14.6.3 ASIA-PACIFIC
14.6.4 Medio Oriente y ÁFRICA
14.6.5 SOUTH AMERICA
14.7 ASIA-PACIFIC PEDIATRIC SPECIALTY HOSPITALS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
14.7.1 NORTH AMERICA
14.7.2 EUROPA
14.7.3 ASIA-PACIFIC
14.7.4 Medio Oriente y ÁFRICA
14.7.5 SOUTH AMERICA
15 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL
15.1 Examen general
15.2 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
15.2.1 HOSPITAL PHARMACY
15.2.2 PHARMACY ESPECIAL
15.2.3 RETAIL PHARMACY
15.2.4 PHARMACY ONLINE
15.3 HOSPITAL ASIA-PACIFIC PHARMACY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (US$ THOUSAND)
15.3.1 NORTE AMERICA
15.3.2 EUROPA
15.3.3 ASIA-PACIFIC
15.3.4 ORIENTE MEDIO Y ÁFRICA
15.3.5 SOUTH AMERICA
15.4 ASIA-PACIFIC SPECIALTY PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
15.4.1 NORTH AMERICA
15.4.2 EUROPA
15.4.3 ASIA-PACIFIC
15.4.4 ORIENTE MEDIO Y ÁFRICA
15.4.5 SOUTH AMERICA
15.5 PHARMACIDAD RETAIL ASIA-PACIFIC EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
15.5.1 NORTE AMERICA
15.5.2 EUROPA
15.5.3 ASIA-PACIFIC
15.5.4 ORIENTE MEDIO Y ÁFRICA
15.5.5 SOUTH AMERICA
16 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION
16.1 ASIA PACIFIC
16.1.1 JAPÓN
16.1.2 CHINA
16.1.3 SOUTH KOREA
16.1.4 INDIA
16.1.5 SINGPORE
16.1.6 THAILAND
16.1.7 INDONESIA
16.1.8 MALAYSIA
16.1.9 PHILIPPINES
16.1.10 BELGIUM
16.1.11 NUEVA ZELANDA
16.1.12 HONG KONG
16.1.13 TAIWAN
16.1.14 REST OF ASIA-PACIFIC
17 ASIA-PACIFIC ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: COMPANY LANDSCAPE
17.1 MANUFACTURER COMPANY SHARE ANALYSIS: GLOBAL
18 ANALISIS SWOT
19 PROFILES DE EMPRESA
19.1 FRESENIUS KABI
19.1.1 SNAPSHOT
19.1.2 ANÁLISIS REVENIDO
19.1.3 COMPANY SHARE ANALISIS
19.1.4 PRODUCTO PORTFOLIO
19.1.5 DESARROLLO RECIENTE
19.2 BAXTER INTERNATIONAL INC.
19.2.1 SNAPSHOT COMPANY
19.2.2 ANÁLISIS REVENIDO
19.2.3 COMPANY SHARE ANALISIS
19.2.4 PRODUCTO PORTFOLIO
19.2.5 DESARROLLO RECIENTE
19.3 NESTLÉ HEALTH SCIENCE
19.3.1
19.3.2 ANÁLISIS REVENIDO
19.3.3 COMPANY SHARE ANALISIS
19.3.4 PRODUCTO PORTFOLIO
19.3.5 DESARROLLO RECIENTE
19.4 LABORATORIAS ABBOTT
19.4.1
19.4.2 ANÁLISIS REVENIDO
19.4.3 COMPANY SHARE ANALISIS
19.4.4 PRODUCTO PORTFOLIO
19.4.5 DESARROLLO RECIENTE
19.5 TAKEDA PHARMACEUTICAL COMPANY LIMITADA
19.5.1 SNAPSHOT
19.5.2 ANÁLISIS REVENIDO
19.5.3 ANÁLISIS DE COMPANÍA
19.5.4 PRODUCTO PORTFOLIO
19.5.5 DESARROLLO RECIENTE
19.6 MOOG COMPANY
19.6.1 SNAPSHOT
19.6.2 ANÁLISIS REVENIDO
19.6.3 PRODUCTO PORTFOLIO
19.6.4 RECENT DEVELOPMENT/NEWS
19.7 ACULIFE HEALTHCARE
19.7.1
19.7.2 PRODUCTO PORTFOLIO
19.7.3 DESARROLLO RECIENTE
19.8 AMSINO INTERNATIONAL, INC
19.8.1 SNAPSHOT
19.8.2 PRODUCTO PORTFOLIO
19.8.3 DESARROLLO RECIENTE
19.9 AURORA
19.9.1
19.9.2 PRODUCTO PORTFOLIO
19.9.3 DESARROLLO RECIENTE
19.1 AMERIPHARMA Cuidado especial.
19.10.1 SNAPSHOT
19.10.2 PRODUCTO PORTFOLIO
19.10.3 DESARROLLO RECIENTE
19.11 Principales empresas de salud
19.11.1
19.11.2 ANÁLISIS REVENIDO
19.11.3 PRODUCTO PORTFOLIO
19.11.4 DESARROLLO RECIENTE
19.12 VELIGROSAS DIGESTIVE CARE
19.12.1
19.12.2 PRODUCTO PORTFOLIO
19.12.3 DESARROLLO RECIENTE
19.13 B. BRAUN SE
19.13.1
19.13.2 PRODUCTO PORTFOLIO
19.13.3 DESARROLLO RECIENTE
19.14 CAMVITTA
19.14.1
19.14.2 PRODUCTO PORTFOLIO
19.14.3 DESARROLLO RECIENTE
19.15 CHOICE PARENTERAL NUTRITION LLC
19.15.1
19.15.2 PRODUCTO PORTFOLIO
19.15.3 DESARROLLO RECIENTE
19.16 CONTINUUMRX
19.16.1
19.16.2 PRODUCTO PORTFOLIO
19.16.3 DESARROLLO RECIENTE
19.17 PHARMACEUTICAS
19.17.1
19.17.2 PRODUCTO PORTFOLIO
19.17.3 DESARROLLO RECIENTE
19.18 GRIFOLS S.A.
19.18.1
19.18.2 ANÁLISIS REVENIDO
19.18.3 PRODUCTO PORTFOLIO
19.18.4 DESARROLLO RECIENTE
19.19 PHARMACEUTICAS HIKMA
19.19.1
19.19.2 ANÁLISIS REVENIDO
19.19.3 PRODUCTO PORTFOLIO
19.19.4 DESARROLLO RECIENTE
19.2 HOSPIRA (PART OF PFIZER INC.)
19.20.1
19.20.2 ANÁLISIS REVENIDO
19.20.3 PRODUCTO PORTFOLIO
19.20.4 DESARROLLO RECIENTE
19.21 HANMI PHARM.CO.,LTD.
19.21.1
19.21.2 ANÁLISIS REVENIDO
19.21.3 PRODUCTO PORTFOLIO
19.21.4 DESARROLLO RECIENTE
19.22 MEDICAL DE UCI, INC.
19.22.1
19.22.2 ANÁLISIS REVENIDO
19.22.3 PRODUCTO PORTFOLIO
19.22.4 DESARROLLO RECIENTE
19.23 SOLUCIONES DE INFUSIÓN
19.23.1
19.23.2 PRODUCTO PORTFOLIO
19.23.3 DESARROLLO RECIENTE
19.24 SISTEMAS DE CARE INTEGRAADOS
19.24.1 SNAPSHOT
19.24.2 PRODUCTO PORTFOLIO
19.24.3 DESARROLLO RECIENTE
19.25 JEDUX PARENTERAL PRIVATE LIMITADA
19.25.1
19.25.2 PRODUCTO PORTFOLIO
19.25.3 DESARROLLO RECIENTE
19.26 LABORATOIRE DIELEN
19.26.1 SNAPSHOT COMPANY
19.26.2 PRODUCTO PORTFOLIO
19.26.3 DESARROLLO RECIENTE
19.27 NAPO THERAPEUTICS.
19.27.1
19.27.2 PRODUCTO PORTFOLIO
19.27.3 RECENT DEVELOPMENT/NEWS
19.28 NUTREGO
19.28.1 SNAPSHOT
19.28.2 PRODUCTO PORTFOLIO
19.28.3 DESARROLLO RECIENTE
19.29 NUTRICIA (Grupo de Dinamarca)
19.29.1 SNAPSHOT
19.29.2 ANÁLISIS REVENIDO
19.29.3 PRODUCTO PORTFOLIO
19.29.4 DESARROLLO RECIENTE
19.3 NUTRICIA NORTH AMERICA
19.30.1
19.30.2 PRODUCTO PORTFOLIO
19.30.3 DESARROLLO RECIENTE
19.31 NUTRISHARE
19.31.1
19.31.2 PRODUCTO PORTFOLIO
19.31.3 DESARROLLO RECIENTE
19.32 OXTHERA
19.32.1
19.32.2 PRODUCTO PORTFOLIO
19.32.3 DESARROLLO RECIENTE
19.33 PHARMKO, INC.
19.33.1
19.33.2 PRODUCTO PORTFOLIO
19.33.3 DESARROLLO RECIENTE
19.34 PUERTO LIFE SCIENCES PVT. LTD.
19.34.1 COMPANY SNAPSHOT
19.34.2 PRODUCTO PORTFOLIO
19.34.3 DESARROLLO RECIENTE
19.35 SHANDONG QIDU PHARMACEUTICAL CO., LTD.
19.35.1 SNAPSHOT COMPANY
19.35.2 PRODUCTO PORTFOLIO
19.35.3 DESARROLLO RECIENTE
19.36 Cuidado de la salud permanente
19.36.1
19.36.2 PRODUCTO PORTFOLIO
19.36.3 DESARROLLO RECIENTE
19.37 UF HEALTH
19.37.1
19.37.2 PRODUCTO PORTFOLIO
19.37.3 DESARROLLO RECIENTE
19.38 PHARMACEUTICAS IRONWOOD
19.38.1
19.38.2 ANÁLISIS REVENIDO
19.38.3 PRODUCTO PORTFOLIO
19.38.4 DESARROLLO RECIENTE
19.39 VISION PARENTERAL
19.39.1 COMPANY SNAPSHOT
19.39.2 PRODUCTO PORTFOLIO
19.39.3 DESARROLLO RECIENTE
19.4 ZEALAND PHARMA
19.40.1
19.40.2 ANÁLISIS REVENIDO
19.40.3 PRODUCTO PORTFOLIO
19.40.4 DESARROLLO RECIENTE
20 CUESTIÓN
21 INFORMES CONEXOS
Lista de Tablas
CUADRO 1 TREATMENTO DE LOS PACIENTES DEL OSE-IF
CUADRO 2 POBLACIONES PACIENTES ESTIMADAS
Cuadro 3
TABLE 4 KEY INDUSTRY INSIGHTS AND MARKET TRENDS IN THE ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET
TABLE 5 IMPACT OF WAR-DRIVEN DISRUPTIONS ON THE ASIA-PACIFIC TYPE 1 SBS-IF TREATMENT MARKET ECOSYSTEM AND INDUSTRY RESPONSE FRAMEWORK
CUADRO 6 DISTRIBUCIÓN DE PRODUCTOS Y PROYECTOS POR FASE ASIA-PACIFIC TYPE 1 SBS-IF MARKET
CUADRO 7 DISTRIBUCIÓN DE LOS PROYECTOS POR APROBADO CIENTÍFICO Y FASE – ASIA-PACIFIC TYPE 1 SBS-IF MARKET
CUADRO 8 DISTRIBUCIÓN DE PROYECTOS POR EL AREA Y LA FASE THERAPEUTIC TYPE 1 SBS-IF MARKET
CUADRO 9 PIPELINE LANDSCAPE Y DESARROLLO CLINICO
CUADRO 10 TÉCNICAS BASADAS EN GLANCE R Pulido – ASIA-PACIFIC TYPE 1 MERCADO DE TRATAMIENTO SBS-IF
CUADRO 11 CANDIDATOS PRECLINICOS/RESEARCH
TABLE 12 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
TABLE 13 ASIA-PACIFIC NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 14 ASIA-PACIFIC PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 15 ASIA-PACIFIC TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 16 ASIA-PACIFIC HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 17 ASIA-PACIFIC HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
CUADRO 18 NUTRICIÓN ENTERAL ASIA-PACIFIC (EN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
CUADRO 19 ASIA-PACIFIC TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 20 ASIA-PACIFIC FORMULA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 21 COMPOSICIÓN PN ASIA-PACIFICA EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 22 ASIA-PACIFIC MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 23 MICRONUTRIENTES ASIA-PACIFICOS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 24 ASIA-PACIFIC NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 25 ASIA-PACIFIC PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 26 ASIA-PACIFIC HORMONAL " INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 27 ANÁLOGOS ASIA-PACIFICOS GLP-2 EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)
TABLE 28 ASIA-PACIFIC GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)
CUADRO 29 ASIA-PACIFIC IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 30 ASIA-PACIFIC ANTI-DIARRHEAL THERAPY EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 31 ASIA-PACIFIC OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 32 ASIA-PACIFIC ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 33 INHIBIdores ASIA-PACIFIC PROTON PUMP EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT con FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
CUADRO 34 ANÁLOGO ASIA-PACIFICO SOMATOSTATIN EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (US$ THOUSAND)
CUADRO 35 ASIA-PACIFIC H2 RECEPTOR ANTAGONISTAS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 36 ASIA-PACIFIC MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 37 ASIA-PACIFIC ANTI-INFECTIVE THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 38 ASIA-PACIFIC BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 39 ASIA-PACIFIC BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 40 ASIA-PACIFIC PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
CUADRO 41 TREATMENTO SURGICANO ASIA-PACIFIC EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 42 PROCEDIMIENTOS INTESTINALES DE LENGTHENING ASIA-PACIFIC EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 43 ASIA-PACIFIC OSTOMY " RECONSTRUCTION IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 44 TRANSPLANTACIÓN INTESTINAL ASIA-PACIFIC EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)
TABLE 45 ASIA-PACIFIC SURGICAL " INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 46 ASIA-PACIFIC EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 47 ASIA-PACIFIC REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 48 ASIA-PACIFIC MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 49 ASIA-PACIFIC GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 50 ASIA-PACIFIC EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 51 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
CUADRO 52 ASIA-PACIFIC CORE SBS-IF MARKET EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)
CUADRO 53 ASIA-PACIFIC CORE SBS-IF MARKET EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (US$ THOUSAND)
CUADRO 54 ASIA-PACIFIC SBS-IF EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 55 ASIA-PACIFIC SBS-IF EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
CUADRO ASIA-PACIFICO / MARCO NO ESPECÍFICO EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR REGION, 2018-2033, (US$ THOUSAND)
TABLE 57 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
TABLE 58 ASIA-PACIFIC ACUTE PHASE (TYPE 1 SBS-IF) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
CUADRO 59 ADAPTACIÓN ASIA-PACIFICA EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (US$ THOUSAND)
CUADRO 60 ASIA-PACIFIC RECOVERY PHASE EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 61 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 62 ASIA-PACIFIC ADULT IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
CUADRO 63 ASIA-PACIFIC PEDIATRIC EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 64 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 65 ASIA-PACIFIC INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 66 ASIA-PACIFIC INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 67 ASIA-PACIFIC SUBCUTANEOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 68 ASIA-PACIFIC ORAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 69 ASIA-PACIFIC ENTERAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 70 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
CUADRO 71 HOSPITALS ASIA-PACIFIC (AUTE CARE) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT con FAILURE INTESTINAL) TREATMENT MARKET, POR REGION, 2018-2033, (US$ THOUSAND)
TABLE 72 ASIA-PACIFIC HOME CARE (HPN PROGRAMS) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT con FAILURE INTESTINAL) TREATMENT MARKET, BY REGION, 2018-2033, (US$ THOUSAND)
TABLE 73 SETTINGS ASIA-PACIFIC ICU EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 74 ASIA-PACIFIC SPECIALTY GI CENTROS EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
CUADRO 75 ASIA-PACIFIC PEDIATRIC SPECIALTY HOSPITALS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
TABLE 76 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
CUADRO 77 ASIA-PACIFIC HOSPITAL PHARMACY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (US$ THOUSAND)
TABLE 78 ASIA-PACIFIC SPECIALTY PHARMACY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY REGION, 2018-2033, (USD THOUSAND)
CUADRO 79 PHARMACÍA RETAIL ASIA-PACIFICA EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, BY REGION, 2018-2033, (US$ THOUSAND)
TABLE 80 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, 2018-2033 (USD THOUSAND)
TABLE 81 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY COUNTRY, 2018-2033 (USD THOUSAND)
CUADRO 82 USD
TABLE 83 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
TABLE 84 ASIA-PACIFIC NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 85 ASIA-PACIFIC PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 86 ASIA-PACIFIC TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 87 ASIA-PACIFIC HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 88 ASIA-PACIFIC HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
CUADRO 89 NUTRICIÓN ENTERAL ASIA-PACIFIC (EN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)
TABLE 90 ASIA-PACIFIC TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 91 ASIA-PACIFIC FORMULA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 92 ASIA-PACIFIC PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 93 ASIA-PACIFIC MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 94 MICRONUTRIENTES ASIA-PACIFICOS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 95 ASIA-PACIFIC PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 96 ASIA-PACIFIC HORMONAL " INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 97 ANALOGOS ASIA-PACIFIC GLP-2 EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)
TABLE 98 ASIA-PACIFIC GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)
TABLE 99 ASIA-PACIFIC IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 100 ASIA-PACIFIC ANTI-DIARRHEAL THERAPY EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 101 ASIA-PACIFIC OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 102 ASIA-PACIFIC ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 103 ASIA-PACIFIC PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 104 ASIA-PACIFIC SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)
TABLE 105 ASIA-PACIFIC H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 106 ASIA-PACIFIC MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 107 ASIA-PACIFIC ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 108 ASIA-PACIFIC BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 109 ASIA-PACIFIC BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 110 ASIA-PACIFIC SURGICAL " INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 111 ASIA-PACIFIC INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 112 ASIA-PACIFIC OSTOMY " RECONSTRUCTION IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 113 ASIA-PACIFIC INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 114 ASIA-PACIFIC EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 115 ASIA-PACIFIC REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 116 ASIA-PACIFIC MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 117 ASIA-PACIFIC GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 118 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
CUADRO 119 ASIA-PACIFIC CORE SBS-IF MARKET EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
TABLE 120 ASIA-PACIFIC SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 121 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
TABLE 122 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 123 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 124 ASIA-PACIFIC INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 125 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 126 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
CUADRO 127 USD
TABLE 128 JAPÓN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
TABLE 129 JAPÓN NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 130 JAPÓN PARENTERAL NUTRITION (PN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 131 JAPÓN TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 132 JAPÓN HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
CUADRO 133 JAPÓN HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
CUADRO 134 JAPÓN ENTERAL NUTRITION (EN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 135 JAPÓN TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 136 JAPAN FORMULA TYPE EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 137 JAPÓN PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 138 MACRONUTRIENTES JAPÓN EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 139 MICRONUTRIENTES JAPÓN EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 140 JAPÓN PHARMACOLOGICAL THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED THOUSAND)
CUADRO 141 JAPÓN HORMONAL " INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 142 ARMAS JAPÓN GLP-2 EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 143 JAPÓN GROWTH HORMONE THERAPY EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)
CUADRO 144 JAPÓN IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 145 JAPAN ANTI-DIARRHEAL THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 146 JAPÓN OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 147 JAPAN ANTI-SECRETORY THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 148 JAPÓN PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 149 ANALOGÍAS SOMATOSTATIN JAPÓN EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE , 2018-2033 (US$ THOUSAND)
CUADRO 150 ANTAGONISTAS DE H2 JAPÓN EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)
TABLE 151 JAPÓN MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 152 JAPAN ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 153 ACID DE JAPÓN " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 154 JAPAN BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 155 JAPÓN SURGICAL " INTERVENTIONAL TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 156 PROCEDIMIENTOS DE LENGTHENING INTESTINAL EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)
CUADRO 157 DE LA OSTOMÍA Y RECONSTRUCCIÓN EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 158 JAPÓN TRANSPLANTACIÓN INTESTINAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 159 JAPÓN EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 160 JAPÓN MEDICINA REGENERATIVO EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 161 JAPÓN MICROBIOME-BASED THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT con FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
TABLE 162 JAPAN GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 163 JAPÓN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
CUADRO 164 JAPÓN CORE SBS-IF MARKET EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 165 JAPÓN SBS-IF MERCADO EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (USTED)
TABLE 166 JAPÓN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
TABLE 167 JAPÓN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 168 JAPÓN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 169 JAPÓN INTRAVENOUS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 170 JAPÓN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 171 JAPÓN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
CUADRO 172 USD
TABLE 173 CHINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
TABLE 174 CHINA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 175 CHINA PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 176 CHINA TOTAL PARENTERAL NUTRITION (TPN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
CUADRO 177 CHINA HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
CUADRO 178 CHINA HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
CUADRO 179 CHINA ENTERAL NUTRITION (EN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 180 CHINA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 181 CHINA FORMULA TYPE EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 182 CHINA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 183 CHINA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 184 MICRONUTRIENTS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 185 CHINA PHARMACOLOGICAL THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
TABLE 186 CHINA HORMONAL " INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 187 CHINA GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 188 CHINA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)
CUADRO 189 CHINA IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 190 CHINA ANTI-DIARRHEAL THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 191 CHINA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 192 CHINA ANTI-SECRETORY THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 193 CHINA PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 194 CHINA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)
TABLE 195 CHINA H2 RECEPTOR ANTAGONISTS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 196 CHINA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 197 CHINA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 198 CHINA BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 199 CHINA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 200 CHINA TREATMENT SURGICAL " INTERVENTIONAL EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 201 CHINA PROCEDIMIENTOS DE LENGTHENING INTESTINAL EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 202 CHINA OSTOMY " RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 203 CHINA TRANSPLANTATION INTESTINAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 204 CHINA EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 205 CHINA MEDICINA REGENERATIVE EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 206 CHINA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 207 CHINA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 208 CHINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
TABLE 209 CHINA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 210 CHINA SBS-IF MARKET ATTRIBUTABLE EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
TABLE 211 CHINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
TABLE 212 CHINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
CUADRO 213 CHINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 214 CHINA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 215 CHINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 216 CHINA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
CUADRO 217 USD
TABLE 218 SOUTH KOREA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
TABLE 219 SOUTH KOREA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 220 SOUTH PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 221 SOUTH KOREA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 222 SOUTH KOREA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 223 SOUTH KOREA HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
TABLE 224 SOUTH KOREA ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 225 SOUTH KOREA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 226 SOUTH KOREA FORMULA TYPE EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 227 SOUTH KOREA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 228 SOUTH KOREA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 229 SOUTH KOREA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 230 SOUTH KOREA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 231 SOUTH KOREA HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 232 ANALOGOS SOUTH GLP-2 EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)
TABLE 233 SOUTH KOREA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)
TABLE 234 SOUTH KOREA IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 235 SOUTH KOREA ANTI-DIARRHEAL THERAPY EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 236 SOUTH KOREA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 237 SOUTH KOREA ANTI-SECRETORY THERAPY EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 238 INHIBITORES DE PUMP DE COREA SUR EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT con FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)
CUADRO 239 ANALOGOS SUR DE COREA SOMATOSTATIN EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT con FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE , 2018-2033 (US$ THOUSAND)
CUADRO 240 ANTAGONISTAS DE RECEPTOR H2 en TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT con FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)
CUADRO 241 SUPLEMENTO DE MICRONUTRIENTE SUR EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)
TABLE 242 SOUTH KOREA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 243 SOUTH KOREA BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 244 SOUTH KOREA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 245 SOUTH KOREA SURGICAL ' INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 246 PROCEDIMIENTOS DE LENGTHENING INTESTINAL EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)
TABLE 247 SOUTH KOREA OSTOMY ' RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 248 SOUTH KOREA INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 249 SOUTH KOREA EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 250 SOUTH KOREA REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 251 SUR KOREA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 252 SOUTH KOREA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 253 SOUTH KOREA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
TABLE 254 SOUTH KOREA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 255 SOUTH KOREA SBS-IF EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 256 SOUTH KOREA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
TABLE 257 SOUTH KOREA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 258 SOUTH KOREA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
CUADRO 259 SOUTH KOREA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 260 SOUTH KOREA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 261 SOUTH KOREA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
CUADRO 262 USD
TABLE 263 INDIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
TABLE 264 INDIA NUTRITIONAL SUPPORT THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 265 INDIA PARENTERAL NUTRITION (PN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 266 INDIA TOTAL PARENTERAL NUTRITION (TPN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
CUADRO 267 INDIA HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
CUADRO 268 INDIA HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
TABLE 269 INDIA ENTERAL NUTRITION (EN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 270 INDIA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 271 INDIA FORMULA TYPE EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 272 INDIA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 273 INDIA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 274 INDIA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 275 INDIA PHARMACOLOGICAL THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 276 INDIA HORMONAL " INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 277 INDIA GLP-2 ANALOGUES EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 278 INDIA GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)
CUADRO 279 INDIA IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 280 INDIA ANTI-DIARRHEAL THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 281 INDIA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 282 INDIA ANTI-SECRETORY THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 283 INDIA PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 284 INDIA SOMATOSTATIN ANALOGUES EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)
CUADRO 285 INDIA H2 RECEPTOR ANTAGONISTAS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
TABLE 286 INDIA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 287 INDIA ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 288 INDIA BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 289 INDIA BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 290 INDIA SURGICAL " INTERVENTIONAL TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 291 INDIA PROCEDIMIENTOS DE LENGTHENING INTESTINAL EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 292 INDIA OSTOMY " RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 293 INDIA TRANSPLANTACIÓN INTESTINAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 294 INDIA EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 295 INDIA MEDICINA REGENERATIVO EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 296 INDIA MICROBIOME-BASED THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 297 INDIA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 298 INDIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
TABLE 299 INDIA CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 300 INDIA SBS-IF MARKET ATTRIBUTABLE EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
TABLE 301 INDIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
TABLE 302 INDIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 303 INDIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 304 INDIA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 305 INDIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 306 INDIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
CUADRO 307 USD
TABLE 308 SINGAPORE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
TABLE 309 SINGAPORE NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 310 SINGAPORE PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 311 SINGAPORE TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 312 SINGAPORE HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 313 SINGAPORE HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
TABLE 314 SINGAPORE ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 315 SINGAPORE TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 316 SINGAPORE FORMULA TYPE EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 317 SINGAPORE PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 318 MACRONUTRIENTES SINGAPORE EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 319 MICRONUTRIENTES SINGAPORE EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 320 SINGAPORE PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 321 SINGAPORE HORMONAL " INTESTINAL ADAPTATION THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 322 SINGAPORE GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 323 SINGAPORE GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)
TABLE 324 SINGAPORE IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 325 SINGAPORE ANTI-DIARRHEAL THERAPY EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 326 SINGAPORE OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 327 SINGAPORE ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 328 SINGAPORE PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 329 ANÁLOGO SOMATOSTATIN EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)
TABLE 330 SINGAPORE H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT con FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
TABLE 331 SINGAPORE MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 332 SINGAPORE ANTI-INFECTIVE THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 333 SINGAPORE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 334 SINGAPORE BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 335 SINGAPORE SURGICAL " INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 336 PROCEDIMIENTOS DE LENGTHENING INTESTINAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)
TABLE 337 SINGAPORE OSTOMY ' RECONSTRUCTION IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 338 SINGAPORE INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 339 SINGAPORE EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 340 SINGAPORE REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 341 SINGAPORE MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 342 SINGAPORE GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 343 SINGAPORE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
TABLE 344 SINGAPORE CORE SBS-IF MARKET EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 345 SINGAPORE SBS-IF EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 346 SINGAPORE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
TABLE 347 SINGAPORE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 348 SINGAPORE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 349 SINGAPORE INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 350 SINGAPORE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 351 SINGAPORE TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
CUADRO 352 USD
TABLE 353 THAILAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
TABLE 354 THAILAND NUTRITIONAL SUPPORT THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 355 THAILAND PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 356 THAILAND TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 357 THAILAND HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 358 THAILAND HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
CUADRO 359 THAILAND ENTERAL NUTRITION (EN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 360 THAILAND TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 361 THAILAND FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 362 THAILAND PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 363 THAILAND MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 364 THAILAND MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 365 THAILAND PHARMACOLOGICAL THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 366 THAILAND HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 367 ARMAS GLP-2 EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 368 THAILAND GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)
TABLE 369 THAILAND IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 370 THAILAND ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 371 THAILAND OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 372 THAILAND ANTI-SECRETORY THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 373 THAILAND PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 374 ANÁLOGO SOMATOSTATIN EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)
CUADRO 375 THAILAND H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 376 THAILAND MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 377 THAILAND ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 378 MODIFICADORES DE ABSORPCIÓN EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 379 TEAILAND BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 380 THAILAND SURGICAL " INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 381 THAILAND INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 382 THAILAND OSTOMY ' RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 383 THAILAND INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 384 THAILAND EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 385 THAILAND REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 386 THAILAND MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 387 THAILAND GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 388 THAILAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
TABLE 389 THAILAND CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 390 THAILAND SBS-IF EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 391 THAILAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
TABLE 392 THAILAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 393 THAILAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
CUADRO 394 THAILAND INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 395 THAILAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 396 THAILAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
CUADRO 397 USD
TABLE 398 INDONESIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
TABLE 399 INDONESIA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 400 INDONESIA PARENTERAL NUTRITION (PN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
TABLE 401 INDONESIA TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 402 INDONESIA HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
CUADRO 403 INDONESIA HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
CUADRO 404 INDONESIA ENTERAL NUTRITION (EN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 405 INDONESIA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 406 INDONESIA FORMULA TYPE EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 407 INDONESIA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 408 INDONESIA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 409 INDONESIA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 410 INDONESIA PHARMACOLOGICAL THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT con FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
TABLE 411 INDONESIA HORMONAL " INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 412 INDONESIA GLP-2 ANALOGUES EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
TABLE 413 INDONESIA GROWTH HORMONE THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USTED)
CUADRO 414 INDONESIA IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
TABLE 415 INDONESIA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 416 INDONESIA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 417 INDONESIA ANTI-SECRETORY THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT con FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED)
TABLE 418 INDONESIA PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
CUADRO 419 INDONESIA SOMATOSTATIN ANALOGUES EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (US$ THOUSAND)
CUADRO 420 INDONESIA H2 RECEPTOR ANTAGONISTAS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
CUADRO 421 INDONESIA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 422 INDONESIA ANTI-INFECTIVE THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 423 INDONESIA BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 424 INDONESIA BILE ACID SEQUESTRANTS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
TABLE 425 INDONESIA TREATMENTO SURGICO e INTERVENTIONAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 426 INDONESIA PROCEDIMIENTOS DE LENGTHENING INTESTINAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 427 INDONESIA OSTOMY " RECONSTRUCCIÓN EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED THOUSAND)
CUADRO 428 INDONESIA TRANSPLANTACIÓN INTESTINAL EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)
TABLE 429 INDONESIA EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 430 INDONESIA MEDICINA REGENERATIVO EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 431 INDONESIA MICROBIOME-BASED THERAPY EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 432 INDONESIA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 433 INDONESIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
CUADRO 434 INDONESIA CORE SBS-IF MARKET EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
CUADRO 435 INDONESIA SBS-IF EN TYPE 1 SBS-IF (SYNDROME BOWEL SYNDROME CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)
CUADRO 436 INDONESIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
TABLE 437 INDONESIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
CUADRO 438 INDONESIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 439 INDONESIA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 440 INDONESIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 441 INDONESIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
CUADRO 442 USD
CUADRO 443 MALAYSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
CUADRO 444 MALAYSIA NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 445 MALAYSIA PARENTERAL NUTRITION (PN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 446 MALAYSIA TOTAL PARENTERAL NUTRITION (TPN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 447 MALAYSIA HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
CUADRO 448 MALAYSIA HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
CUADRO 449 MALAYSIA ENTERAL NUTRITION (EN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 450 MALAYSIA TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 451 MALAYSIA FORMULA TYPE EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 452 MALAYSIA PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 453 MALAYSIA MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 454 MALAYSIA MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 455 MALAYSIA PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 456 MALAYSIA HORMONAL " INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 457 MALAYSIA GLP-2 ANALOGUES EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)
TABLE 458 MALAYSIA GROWTH HORMONE THERAPY EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)
CUADRO 459 MALAYSIA IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
TABLE 460 MALAYSIA ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 461 MALAYSIA OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 462 MALAYSIA ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 463 MALAYSIA PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)
CUADRO 464 MALAYSIA SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)
CUADRO 465 MALAYSIA H2 RECEPTOR ANTAGONISTAS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 466 MALAYSIA MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 467 MALAYSIA ANTI-INFECTIVE THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 468 MALAYSIA BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 469 MALAYSIA BILE ACID SEQUESTRANTS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)
CUADRO 470 MALAYSIA SURGICAL " INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 471 MALAYSIA PROCEDIMIENTOS DE LENGTHENING INTESTINAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED)
CUADRO 472 MALAYSIA OSTOMY ' RECONSTRUCTION IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
CUADRO 473 MALAYSIA TRANSPLANTACIÓN INTESTINAL EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)
TABLE 474 MALAYSIA EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 475 MALAYSIA MEDICINA REGENERATIVO EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 476 MALAYSIA MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 477 MALAYSIA GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 478 MALAYSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
CUADRO 479 MALAYSIA CORE SBS-IF MARKET EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)
CUADRO 480 MALAYSIA SBS-IF EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 481 MALAYSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
TABLE 482 MALAYSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
CUADRO 483 MALAYSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
CUADRO 484 MALAYSIA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 485 MALAYSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 486 MALAYSIA TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
CUADRO 487 USD
TABLE 488 PHILIPPINES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
TABLE 489 PHILIPPINES NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 490 PHILIPPINES PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 491 PHILIPPINES TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 492 PHILIPPINES HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 493 PHILIPPINES HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
CUADRO 494 PHILIPPINES ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 495 PHILIPPINES TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 496 PHILIPPINES FORMULA TYPE EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 497 PHILIPPINES PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 498 PHILIPPINES MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 499 PHILIPPINES MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 500 PHILIPPINES PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 501 PHILIPPINES HORMONAL & INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 502 PHILIPPINES GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 503 PHILIPPINES GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)
CUADRO 504 PHILIPPINES IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 505 PHILIPPINES ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 506 PHILIPPINES OPIOID-BASED IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
TABLE 507 PHILIPPINES ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 508 PHILIPPINES PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 509 PHILIPPINES SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)
TABLE 510 PHILIPPINES H2 RECEPTOR ANTAGONISTAS EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 511 PHILIPPINES MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 512 PHILIPPINES ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 513 PHILIPPINES BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 514 PHILIPPINES BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 515 PHILIPPINES SURGICAL ' INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 516 PHILIPPINES INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 517 PHILIPPINES OSTOMY ' RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 518 PHILIPPINES INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 519 PHILIPPINES EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 520 PHILIPPINES REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 521 PHILIPPINES MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 522 PHILIPPINES GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 523 PHILIPPINES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
CUADRO 524 PHILIPPINES CORE SBS-IF MARKET EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT con FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
CUADRO 525 PHILIPPINES SBS-IF EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 526 PHILIPPINES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
TABLE 527 PHILIPPINES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 528 PHILIPPINES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
CUADRO 529 PHILIPPINES INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 530 PHILIPPINES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 531 PHILIPPINES TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
CUADRO 532 USD
TABLE 533 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
TABLE 534 BELGIUM NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 535 BELGIUM PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 536 BELGIUM TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 537 BELGIUM HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 538 BELGIUM HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
CUADRO 539 BELGIUM ENTERAL NUTRITION (EN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL BOWEL CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)
TABLE 540 BELGIUM TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 541 BELGIUM FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 542 BELGIUM PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 543 BELGIUM MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 544 MICRONUTRIENTES BELGIUM EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 545 BELGIUM PHARMACOLOGICAL THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT con FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
TABLE 546 BELGIUM HORMONAL " INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 547 ANALOGOS BELGIUM GLP-2 EN TYPE 1 SBS-IF (SYNDROME DE BOWEL BOWEL CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)
TABLE 548 BELGIUM GROWTH HORMONE THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USTED)
TABLE 549 BELGIUM IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL con FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
TABLE 550 BELGIUM ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 551 BELGIUM OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 552 BELGIUM ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 553 BELGIUM PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL BOWEL CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)
CUADRO 554 ANÁLOGO SOMATOSTATIN EN TYPE 1 SBS-IF (SYNDROME DE BOWEL BOWEL CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE , 2018-2033 (US$ THOUSAND)
TABLE 555 BELGIUM H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 556 BELGIUM MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 557 BELGIUM ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SYNDROME BOWEL BOWEL CON FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
TABLE 558 BELGIUM BILE ACID " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 559 BELGIUM BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SYNDROME BOWEL BOWEL CON FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
TABLE 560 BELGIUM SURGICAL " INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 561 BELGIUM INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 562 BELGIUM OSTOMY ' RECONSTRUCTION IN TYPE 1 SBS-IF (SYNDROME DE BOWEL CON FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED THOUSAND)
TABLE 563 BELGIUM INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 564 BELGIUM EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 565 BELGIUM REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 566 BELGIUM MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 567 BELGIUM GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 568 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
TABLE 569 BELGIUM CORE SBS-IF MARKET EN TYPE 1 SBS-IF (SYNDROME DE BOWEL BOWEL CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE, 2018-2033 (US$ THOUSAND)
TABLE 570 BELGIUM SBS-IF EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 571 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
TABLE 572 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 573 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 574 BELGIUM INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 575 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 576 BELGIUM TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
CUADRO 577 USD
CUADRO 578 NEW ZEALAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
CUADRO 579 NEW ZEALAND NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 580 NUEVA ZELANDA PARENTERAL NUTRITION (PN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 581 NUEVA ZELANDA TOTAL PARENTERAL NUTRITION (TPN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 582 NEW ZEALAND HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
CUADRO 583 NEW ZEALAND HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
CUADRO 584 NUEVA ZELANDA ENTERAL NUTRITION (EN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED THOUSAND)
CUADRO 585 NEW ZEALAND TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 586 NEW ZEALAND FORMULA TYPE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 587 NEW ZEALAND PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 588 NEW ZEALAND MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 589 NUEVAS MICRONUTRIENTES DE ZELANDA EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
CUADRO 590 NEW ZEALAND PHARMACOLOGICAL THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 591 NEW ZEALAND HORMONAL " INTESTINAL ADAPTATION THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 592 NUEVA ZELANDA GLP-2 ANÁLOGO EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 593 NEW ZEALAND GROWTH HORMONE THERAPY EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USTED)
CUADRO 594 NEW ZEALAND IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 595 NEW ZEALAND ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 596 NUEVA ZELANDA OPIOID-BASED EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 597 NEW ZEALAND ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 598 NUEVAS INHIBITORES DE PUMP DE ZELANDA EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 599 NUEVAS ANÁLOGO ZEALANDA SOMATOSTATIN EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT CON FAILURE INTESTINAL) TREATMENT MARKET, POR TYPE , 2018-2033 (US$ THOUSAND)
CUADRO 600 NUEVA ZEALANDA H2 RECEPTOR ANTAGONISTAS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 601 NUEVA SUPLEMENTE MICRONUTRIENT EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 602 NEW ZEALAND ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 603 NUEVAS MODIFICACIONES DE ACID DE ZEALANDA EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
CUADRO 604 NUEVO ZEALAND BILE ACID SEQUESTRANTS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 605 NUEVO TRATAMIENTO SURGICO e INTERVENTIONAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 606 NUEVAS PROCEDIMIENTOS DE LENGTHENING INTESTINAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 607 NEW ZEALAND OSTOMY ' RECONSTRUCTION IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 608 NUEVA TRANSPLANTACIÓN INTESTINAL EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 609 NEW ZEALAND EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 610 NEW ZEALAND REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 611 NEW ZEALAND MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 612 NEW ZEALAND GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 613 NEW ZEALAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
CUADRO 614 NEW ZEALAND CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 615 NEW ZEALAND SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 616 NEW ZEALAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
CUADRO 617 NEW ZEALAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
CUADRO 618 NEW ZEALAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
CUADRO 619 NUEVA ZELANDA INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 620 NEW ZEALAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
CUADRO 621 NEW ZEALAND TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
CUADRO 622 USD
TABLE 623 HONG KONG TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
TABLE 624 HONG KONG NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 625 HONG KONG PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 626 HONG KONG TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 627 HONG HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
CUADRO 628 HONG HOME PARENTERAL NUTRITION (HPN) EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
CUADRO 629 HONG KONG ENTERAL NUTRITION (EN) EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED THOUSAND)
TABLE 630 HONG TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 631 HONG KONG FORMULA TYPE EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 632 HONG KONG PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 633 HONG KONG MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 634 HONG MICRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 635 HONG KONG PHARMACOLOGICAL THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT con FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
TABLE 636 HONG KONG HORMONAL " INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 637 HONG KONG GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 638 HONG KONG GROWTH HORMONE THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USTED)
CUADRO 639 HONG KONG IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 640 HONG KONG ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 641 HONG KONG OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 642 HONG KONG ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 643 HONG KONG PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 644 HONG KONG SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)
TABLE 645 HONG KONG H2 RECEPTOR ANTAGONISTAS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT con FAILURE INTESTINAL) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
TABLE 646 HONG KONG MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 647 HONG KONG ANTI-INFECTIVE THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 648 HONG KONG BILE ACID " ABSORPERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 649 HONG KONG BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 650 HONG SURGICAL & INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 651 HONG KONG INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 652 HONG KONG OSTOMY " RECONSTRUCTION IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 653 HONG KONG INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 654 HONG KONG EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 655 HONG KONG REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 656 HONG MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 657 HONG KONG GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 658 HONG KONG TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
TABLE 659 HONG KONG CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 660 HONG KONG SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 661 HONG KONG TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
TABLE 662 HONG KONG TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 663 HONG KONG TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
CUADRO 664 HONG INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 665 HONG KONG TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 666 HONG KONG TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
CUADRO 667 USD
TABLE 668 TAIWAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
TABLE 669 TAIWAN NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 670 TAIWAN PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 671 TAIWAN TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 672 TAIWAN HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 673 TAIWAN HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
CUADRO 674 TAIWAN ENTERAL NUTRITION (EN) EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 675 TAIWAN TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 676 TAIWAN FORMULA TYPE EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 677 TAIWAN PN COMPOSITION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 678 DE TAIWAN MACRONUTRIENTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 679 MICRONUTRIENTS TAIWAN EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 680 TAIWAN PHARMACOLOGICAL THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 681 TAIWAN HORMONAL & INTESTINAL ADAPTATION THERAPY EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 682 TAIWAN GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 683 TAIWAN GROWTH HORMONE THERAPY EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USTED)
CUADRO 684 TAIWAN IGF-1 " ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 685 TAIWAN ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 686 TAIWAN OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 687 TAIWAN ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 688 TAIWAN PROTON PUMP INHIBITORS EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 689 TAIWAN SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)
TABLE 690 TAIWAN H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 691 TAIWAN MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 692 TAIWAN ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED)
TABLE 693 ACID DE TAIWAN " ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 694 TAIWAN BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 695 TAIWAN SURGICAL " INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 696 TAIWAN INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 697 TAIWAN OSTOMY " RECONSTRUCTION IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USTED THOUSAND)
TABLE 698 TAIWAN INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 699 TAIWAN EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 700 TAIWAN REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 701 TAIWAN MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 702 TAIWAN GENE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 703 TAIWAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
CUADRO 704 TAIWAN CORE SBS-IF MARKET EN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (US$ THOUSAND)
TABLE 705 TAIWAN SBS-IF EN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 706 TAIWAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
TABLE 707 TAIWAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 708 TAIWAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
TABLE 709 TAIWAN INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 710 TAIWAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 711 TAIWAN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
CUADRO 712 USD
TABLE 713 REST OF ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY, 2018-2033 (USD THOUSAND)
TABLE 714 REST OF ASIA-PACIFIC NUTRITIONAL SUPPORT THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 715 REST OF ASIA-PACIFIC PARENTERAL NUTRITION (PN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 716 REST OF ASIA-PACIFIC TOTAL PARENTERAL NUTRITION (TPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 717 REST OF ASIA-PACIFIC HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 718 REST OF ASIA-PACIFIC HOME PARENTERAL NUTRITION (HPN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT DURATION, 2018-2033 (USD THOUSAND)
TABLE 719 REST OF ASIA-PACIFIC ENTERAL NUTRITION (EN) IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 720 REST OF ASIA-PACIFIC TUBE FEEDING IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 721 REST OF ASIA-PACIFIC FORMULA TYPE IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 722 REST OF ASIA-PACIFIC PN COMPOSITION IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 723 REST OF ASIA-PACIFIC MACRONUTRIENTS IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 724 REST OF ASIA-PACIFIC MICRONUTRIENTS IN TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 725 REST OF ASIA-PACIFIC PHARMACOLOGICAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 726 REST OF ASIA-PACIFIC HORMONAL ' INTESTINAL ADAPTATION THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 727 REST OF ASIA-PACIFIC GLP-2 ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 728 REST OF ASIA-PACIFIC GROWTH HORMONE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY SOMATROPIN-BASED , 2018-2033 (USD THOUSAND)
CUADRO 729 REST OF ASIA-PACIFIC IGF-1 & ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 730 REST OF ASIA-PACIFIC ANTI-DIARRHEAL THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 731 REST OF ASIA-PACIFIC OPIOID-BASED IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 732 REST OF ASIA-PACIFIC ANTI-SECRETORY THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 733 REST OF ASIA-PACIFIC PROTON PUMP INHIBITORS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 734 REST OF ASIA-PACIFIC SOMATOSTATIN ANALOGUES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE , 2018-2033 (USD THOUSAND)
CUADRO 735 REST OF ASIA-PACIFIC H2 RECEPTOR ANTAGONISTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 736 REST OF ASIA-PACIFIC MICRONUTRIENT SUPPLEMENTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 737 REST OF ASIA-PACIFIC ANTI-INFECTIVE THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 738 REST OF ASIA-PACIFIC BILE ACID & ABSORPTION MODIFIERS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 739 REST OF ASIA-PACIFIC BILE ACID SEQUESTRANTS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 740 REST OF ASIA-PACIFIC SURGICAL " INTERVENTIONAL TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 741 REST OF ASIA-PACIFIC INTESTINAL LENGTHENING PROCEDURES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 742 REST OF ASIA-PACIFIC OSTOMY ' RECONSTRUCTION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 743 REST OF ASIA-PACIFIC INTESTINAL TRANSPLANTATION IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 744 REST OF ASIA-PACIFIC EMERGING " ADVANCED THERAPIES IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 745 REST OF ASIA-PACIFIC REGENERATIVE MEDICINE IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 746 REST OF ASIA-PACIFIC MICROBIOME-BASED THERAPY IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 747 REST OF ASIA-PACIFIC GENE THERAPY IN TYPE 1 SBS-IF (SYNDROME DE BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 748 REST OF ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY MARKET ATTRIBUTION, 2018-2033 (USD THOUSAND)
TABLE 749 REST OF ASIA-PACIFIC CORE SBS-IF MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 750 REST OF ASIA-PACIFIC SBS-IF ATTRIBUTABLE MARKET IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
TABLE 751 REST OF ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISEASE MANAGEMENT PHASE, 2018-2033 (USD THOUSAND)
TABLE 752 REST OF ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY PATIENT TYPE, 2018-2033 (USD THOUSAND)
TABLE 753 REST OF ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2033 (USD THOUSAND)
CUADRO 754 REST OF ASIA-PACIFIC INTRAVENOUS IN TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY TYPE, 2018-2033 (USD THOUSAND)
CUADRO 755 REST OF ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY END USER, 2018-2033 (USD THOUSAND)
TABLE 756 REST OF ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2033 (USD THOUSAND)
Lista de figuras
FIGURE 1 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: MULTIVARIVATE MODELING
FIGURE 10 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: PRODUCT TYPE TIMELINE CURVE
FIGURE 11 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: APPLICATION COVERAGE GRID
FIGURE 12 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: SEGMENTATION
FIGURE 13 FOUR SEGMENTS COMPRISE THE ASIA-PACIFIC TYPE 1 SBS-IF (SYNDROME BOWEL SHORT with INTESTINAL FAILURE) TREATMENT MARKET, BY TREATMENT MODALITY (2025)
FIGURE 14 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: EXECUTIVE SUMMARY
FIGURE 15 RISING SBS-IF PATIENT POPULATION IS EXPECTED TO DRIVE THE ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET DURING THE FORECAST PERIOD OF 2026 TO 2033.
FIGURE 16 NUTRITIONAL SUPPORT THERAPY is EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET IN 2026 & 2033
FIGURE 17 DECISIONES STRATEGIC
FIGURE 18 PESTEL ANALISIS
FIGURE 19 ANALISIS DROC
FIGURE 20 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: BY TREATMENT MODALITY, 2025
FIGURE 21 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: BY MARKET ATTRIBUTION, 2025
FIGURE 22 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: BY DISEASE MANAGEMENT PHASE, 2025
FIGURE 23 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: BY PATIENT TYPE, 2025
FIGURE 24 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2025
FIGURE 25 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: BY END USER, 2025
FIGURE 26 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025
FIGURE 27 ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: SNAPSHOT (2025)
FIGURE 28 ASIA-PACIFIC ASIA-PACIFIC TYPE 1 SBS-IF (SHORT BOWEL SYNDROME with INTESTINAL FAILURE) TREATMENT MARKET: COMPANY SHARE 2025 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
